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The two primary somatosensory pathways for the body (Martin 2003) 
Somatic sensory information from the body is conveyed to the cerebral cortex 
primarily via one of two pathways: the posterior column-medial lemniscal (PCML) 
pathway and the anterolateral system (ALS).  These pathways have several things in 
common: they each have primary sensory neurons located in the dorsal root ganglia 
(DRG), second order neurons located in the ipsilateral central nervous system, and third 
order neurons in the contralateral ventral posterior lateral (VPL) nucleus of the thalamus 
which project to the cortex.  The second order neurons of both pathways cross the 
midline so that sensory perception occurs in cortex contralateral to the side of 
stimulation.  The commonalities end here.  The central axons of ALS DRG neurons enter 
the spinal cord and synapse in the ipsilateral dorsal horn, whereas the central axons of 
PCML neurons enter the spinal cord, ascend in the dorsal columns, and synapse in the 
medullary dorsal column nuclei (Figure 1.1).  The second order neurons for both 
pathways then cross the midline (decussate) and ascend to the VPL nucleus in the 
thalamus. 
In addition to differing anatomically, these two pathways differ in the modalities that 
they convey.  The ALS pathway primarily conveys the sensory modalities of pain, 
temperature, and crude touch, while the PCML pathway primarily conveys the sensory 
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modalities of fine touch, proprioception, and vibration.  ALS DRG neurons generally 
have bare nerve endings that act as the sensory receptors themselves, whereas PCML 
pathway DRG neurons generally have encapsulated nerve endings.  Peripheral axons of 
ALS DRG neurons are endowed with specific sets of proteins that allow them to 
transduce thermal, noxious, or mechanical sensory stimuli into action potentials.  The 
encapsulated nerve endings act as sensory end organs specific to certain mechanical 
stimuli (i.e., stretch, vibration, proprioception, light touch).  
Sensitization and hyperalgesia  
Acute pain occurs in response to potentially damaging stimuli, and its duration and 
intensity correlate with the stimulus.  This makes acute pain adaptive.  Tissue damage, 
inflammation, and nerve damage alter the response properties of primary afferent neurons 
via a process called sensitization, which can lead to chronic maladaptive pain that 
requires clinical treatment.  Sensitization is characterized by decreased firing threshold, 
increased response to suprathreshold stimuli, and spontaneous activity in primary 
afferents. These are the physiological correlates of hyperalgesia as defined by decreased 
pain threshold, increased pain to noxious stimuli, and spontaneous pain, respectively 
(Meyer, M. et al. 2005). 
The process of sensitization involves post-translational modification as well as 
expression dependent changes within primary afferent neurons (Woolf and Costigan 
1999; Costigan and Woolf 2000; Woolf and Salter 2000; Woolf and Ma 2007).    Post-
translational modification can be mediated by sensitizers (i.e., bradykinin, prostaglandins, 
interleukins, protons, ATP, glutamate and nerve growth factor [NGF]) interacting with 
receptors on the membrane of peripheral terminals.  Subsequently, via second messenger 
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and other signaling cascades, proteins such as transient receptor potential receptors 
(TRPs) and voltage-gated sodium channels (Navs) are modified by phosphorylation or 
allosteric modulation (Woolf and Ma 2007).  These alterations increase nerve terminal 
excitability and reduce the activation threshold.   
Increased electrical activity entering the cell body can initiate alterations in gene 
expression.  Furthermore, some signaling molecules, e.g., NGF, can be retrogradely 
transported from the peripheral terminal back to the cell body where they can regulate 
gene expression (Woolf and Ma 2007).  Post-translational modifications of proteins 
already at the peripheral terminal can result in hyperalgesia within seconds to minutes, 
whereas expression-dependent changes take longer to develop and may last for hours, 
days, or longer (Woolf and Costigan 1999).  Expression-dependent changes are thought 
to be necessary for maintaining chronic pain (Bolay and Moskowitz 2002). 
Dorsal root ganglion neuron populations 
DRG neurons can be classified by cell body size, axon diameter, conduction velocity, 
sensory modality, and molecular markers.  The most widely established subdivision of 
DRG neurons is by the size of their cell bodies (Willis and Coggeshall 1991).  Studies 
that are concerned with DRG neurons typically divide cells into two populations: large 
and small.  The evidence that there are at least two populations of DRG neurons based on 
cell body size comes from histograms that relate cell body size (diameter or area) with 
cell number.  A bimodal distribution is often apparent (Figure 1.2) with a tall, but narrow 
small cell peak and a short, but broad large cell peak (Lawson, Harper et al. 1984; Harper 
and Lawson 1985). 
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In addition to two populations of DRG neurons based on size of the cell body, there 
are also two populations based on axon diameter: small and large.  The small neurons 
typically have unmyelinated small diameter axons and the large neurons have myelinated 
large diameter axons (Yoshida and Matsuda 1979; Lee, Chung et al. 1986).  Cell body 
size can, therefore, be used as a predictor of axon diameter.  Axon diameter correlates 
well with conduction velocity as a general physiological principle, and it has been shown 
that large cells with large axons conduct at velocities greater than 2.5 m/s (A fibers) while 
small cells with small axons conduct at velocities less than 2.5 m/s (C fibers) (Lee, 
Chung et al. 1986).  The A fibers can be divided further into Aα/Aβ and Aδ fibers, 
whereby Aα/Aβ fibers conduct faster than Aδ fibers.  The Aα/Aβ fibers belong to the 
large cell population while the Aδ and C fibers appear to belong to the small cell 
population (Harper and Lawson 1985). 
Receptive fields of primary sensory neurons can be tested with various stimuli, both 
noxious and non-noxious, concurrent with electrophysiological recording of the cell body 
to determine the sensory threshold for individual neurons.  Most neurons with conduction 
velocities in the Aα/Aβ range respond to non-noxious stimuli, while most neurons in the 
Aδ and C range respond to noxious and thermal stimuli (Fang, McMullan et al. 2005).  
However, some neurons in the Aα/Aβ range also are nociceptors (Lawson 2002), and 
some unmyelinated fibers signal touch (Douglas and Ritchie 1957).  The anatomical and 
physiological correlations combined with modality specific information can be 
summarized as follows: DRG neurons are roughly divided into large and small cell 
populations that correspond with peripheral terminals that sense non-noxious and noxious 
stimuli, respectively.  There are, of course, many exceptions to this oversimplification, 
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but dividing DRG neurons in this way provides a useful terminology to discuss 
experimental results and is commonly used in contemporary research.  
The reported distributions for most molecular markers of DRG subpopulations vary 
from study to study, but some generalizations can be made.  Large diameter non-
nociceptors typically label for specific, high molecular weight, neurofilament proteins 
(Lawson, Harper et al. 1984). Small diameter nociceptive neurons, which label for the 
neurofilament, peripherin (Goldstein, House et al. 1991), can be roughly divided into 
peptidergic and nonpeptidergic subpopulations.  Peptidergic neurons characteristically 
contain the peptides substance P (SP) and calcitonin gene-related peptide (CGRP), 
whereas nonpeptidergic small diameter neurons do not.  The former population is thought 
to express the high affinity NGF receptor, trkA.  The latter population often is identified 
by labeling with isolectin-B4 (IB4) from the plant Griffonia simplicifolia, which binds to 
α-D-galactosyl residues on proteins or lipids made in these cells (Averill, McMahon et al. 
1995; Priestley, Michael et al. 2002; Fang, Djouhri et al. 2006).    Both types of small 
diameter neurons are considered to be nociceptors (Fang, Djouhri et al. 2006), but they 
have different termination patterns in the periphery and the spinal cord dorsal horn 
(Zylka, Rice et al. 2005).  It has been noted that there is considerable overlap of these two 
populations (Kashiba, Uchida et al. 2001), but these distinctions are still useful.    
The aforementioned classification by molecular markers is the most prevalent used, 
but there are many other proteins that may indicate unique populations of DRG neurons.  
These include the Nav isoforms (Fukuoka, Kobayashi et al. 2008) and TRP receptors 
(Tominaga and Caterina 2004).  There are constantly more markers being proposed to 
identify specific populations of DRG neurons, but as with the established markers, there 
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are often discrepancies as to their exact distribution.  For instance, within a single study, 
the estimated percentages of the TRPV1, a receptor that responds to painful heat 
(Caterina, Schumacher et al. 1997), were staggeringly different between an anatomical 
assay and a functional assay (Bautista, Jordt et al. 2006).  The immunofluorescence 
experiment showed that approximately 25% of mouse DRG neurons immunolabel for 
TRPV1, whereas approximately 75% of neurons responded with calcium imaging after 
capsaicin stimulation (capsaicin is a TRPV1 agonist).  Similarly, estimates of Nav1.8, 
which is thought to be expressed exclusively in nociceptors, were very different between 
two studies.  Immunofluorescence indicated that approximately 50% of adult rat DRG 
neurons express Nav1.8 (Benn, Costigan et al. 2001), whereas in-situ hybridization has 
shown that 66.5-68.9% of DRG neurons express Nav
The amino acid glutamate is widely accepted as the primary excitatory 
neurotransmitter for the central nervous system (CNS), and glutamate metabolism and 
compartmentalization have been well characterized in the CNS (Hertz 2004).  Glutamate 
released from CNS neurons is transported back into neurons, but also into glial cells by 
excitatory amino acid transporters (EAATs).  Glia convert glutamate to glutamine with 
the enzyme glutamine synthetase (GS).  Glutamine is released into the extracellular space 
1.8 (Fukuoka, Kobayashi et al. 
2008).  It would be beneficial to standardize how the distributions of new molecular 
markers are determined by thoroughly optimizing experimental conditions.  This is not 
just a goal for those studying DRG neuron subpopulations, but for any investigations, 
clinical or scientific, where accurate determination of antigen distribution is desired 
(Taylor and Levenson 2006; Walker 2006). 
Glutamate as a neurotransmitter for dorsal root ganglion neurons 
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where it is taken up by neurons via sodium-coupled neutral amino acid transporters 
(SNATs).  Neurons convert glutamine to glutamate with the enzyme glutaminase (GLS).  
Newly synthesized glutamate can be packaged into vesicles by vesicular glutamate 
transporters (VGLUTs) to await synaptic release. 
Many of the proteins involved in this “glutamate-glutamine cycle” have been 
localized to the DRG, indicating that glutamate metabolism in the peripheral nervous 
system has similarities with that in the CNS (Figure 1.3).  The neuronal glutamate 
transporter EAAT3 localizes to DRG neurons (Tao, Liaw et al. 2004), while the glial 
glutamate transporter EAAT1 localizes to satellite glial cells (Berger and Hediger 2000).  
GS is found in satellite glial cells of the DRG (Miller, Richards et al. 2002) and 
trigeminal ganglia (TG) (Hanani 2005).  SNAT1 (Miller, Kriebel et al. 2005) and GLS 
(Miller, Douglas et al. 1993) have been detected in DRG neurons.  Presence of the 
abovementioned proteins, in their respective locations within the DRG, suggests that 
glutamate and glutamine exchange and metabolism can occur between peripheral neurons 
and glia. This notion is supported by the in vitro observation that [3H]glutamate is 
transported into satellite glial cells (Roberts and Keen 1974; Duce and Keen 1983) while 
[3
Presence of VGLUTs in neurons is, in contrast, an extremely specific indicator of 
glutamatergic neurons, because they are necessary for filling synaptic vesicles with 
glutamate.  VGLUTs have been localized to neuronal cell bodies of the DRG (Oliveira, 
H]glutamine is transported into DRG neurons and quickly converted to glutamate 
(Duce and Keen 1983).  These findings, however, do not necessarily implicate glutamate 
as a neurotransmitter of DRG neurons since glutamate can also be used as an energy 
substrate for the TCA cycle (McKenna 2007).   
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Hydling et al. 2003; Brumovsky, Watanabe et al. 2007) and TG (Li, Xiong et al. 2003).  
Furthermore, they have been localized to regions of the spinal and medullary dorsal horn 
where DRG and TG neurons synapse, respectively (Li, Fujiyama et al. 2003).  In 
addition, it has been suggested that certain populations of primary afferents release 
glutamate as neurotransmitter from their peripheral terminals (Carlton 2001), and 
localization of VGLUTs to peripheral terminals (Nunzi, Pisarek et al. 2004; Brumovsky, 
Watanabe et al. 2007) gives further support for this. 
In addition to localizing glutamate-glutamine cycle components to DRG and 
VGLUTs at central and peripheral sites of glutamate release, glutamate concentrations in 
these areas also have been measured during various types of noxious stimulation.  The 
concentration of extracellular glutamate increases in rat dorsal horn after pinching, 
carrageenan induced inflammation (Dmitrieva, Rodriguez-Malaver et al. 2004), plantar 
incision (Zahn, Sluka et al. 2002), formalin injection, and sodium channel activation 
(Skilling, Smullin et al. 1988).  Formalin induced intraplantar inflammation and 
carrageenan induced intraarticular inflammation increase glutamate concentration in the 
subcutaneous tissue (Omote, Kawamata et al. 1998) and synovial fluid (Lawand, 
McNearney et al. 2000), respectively.  Although non-neural sources may contribute to 
these glutamate increases, other studies show support for a neural source, specifically 
primary afferent nociceptors.  Antidromic stimulation of the sciatic nerve results in 
increased extracellular glutamate concentrations in the subcutaneous intraplantar tissue 
(deGroot, Zhou et al. 2000; Jin, Nishioka et al. 2006).  Peripheral inflammation also 
increases the glutamate content of peripheral nerve in monkeys (Westlund, Sun et al. 
1992).  Capsaicin, an agonist of the TRPV1 receptor located on nociceptive primary 
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afferents (Caterina, Schumacher et al. 1997), can selectively stimulate these peripheral 
terminals when applied topically.  Subcutaneous glutamate concentrations increase in 
response to noxious thermal stimulation or capsaicin application, and such increases are 
attenuated with systemic or intraplantar morphine (Jin, Nishioka et al. 2006).  These 
findings indicate that glutamate is released from nociceptor peripheral terminals in 
response to painful stimulation and that activation of opioid receptors on these peripheral 
endings can suppress noxious stimulus-induced glutamate release. 
Glutamate appears to be involved in acute and tonic nociceptive transmission at both 
the central and peripheral terminals of DRG neurons in animal pain models.  Evidence 
for involvement in chronic pain in humans comes from studies of patients with joint or 
skin inflammation.  Patients with chronic arthritis and gold-induced dermatitis showed 
elevated levels of glutamate in the joint (McNearney, Speegle et al. 2000; McNearney, 
Baethge et al. 2004) and skin (Nordlind, Johansson et al. 1993), respectively.  
Antagonism of ionotropic and excitatory metabotropic glutamate receptors at the site of 
inflammation or injury has provided analgesia in many animal studies (Carlton, Hargett 
et al. 1995; Jackson, Graff et al. 1995; Davidson, Coggeshall et al. 1997; Lawand, Willis 
et al. 1997; Bhave, Karim et al. 2001; Leem, Hwang et al. 2001) and for human burn 
injury (Warncke, Jorum et al. 1997).   
Glutamate also is implicated as an acute activator and sensitizer of nociceptive 
primary afferents as it appears to have this ability both ex vivo (Du, Koltzenburg et al. 
2001) and in vivo (Follenfant and Nakamura-Craig 1992; Zhou, Bonasera et al. 1996; Du, 
Zhou et al. 2003).  Primary afferent sensitization in response to glutamate also occurs in 
humans, because subcutaneous injection of glutamate elicits acute pain and subsequent 
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hyperalgesia (Gazerani, Wang et al. 2006).  Presence of glutamate receptors on peripheral 
unmyelinated axons from animals (Carlton, Hargett et al. 1995; Coggeshall and Carlton 
1998; Bhave, Karim et al. 2001) and humans (Kinkelin, Brocker et al. 2000) are further 
support that glutamate is acting directly on nociceptive peripheral terminals.  The primary 
afferent may be, therefore, both the source and the target of peripheral glutamate release 
during noxious stimulation (Carlton 2001). 
Glutamate release from central terminals of DRG neurons increases during 
inflammation (Skilling, Smullin et al. 1988; Dmitrieva, Rodriguez-Malaver et al. 2004), 
and this glutamate, in concert with substance P, is involved in sensitization of the second 
order neurons in the spinal cord dorsal horn (Dougherty and Willis 1991; Dougherty, 
Palecek et al. 1993).  Despite much evidence for glutamate autostimulation and 
sensitization of peripheral primary afferent terminals and dorsal horn neurons during 
inflammation, very little is known about alterations in glutamate metabolism during such 
conditions.  It would be beneficial to determine how constituents of the glutamate-
glutamine cycle are regulated, either via post-translational modification or expression 
changes, during inflammation.  Investigation of glutamate metabolism may reveal novel 
therapeutic targets for treatment of inflammatory pain.  For this dissertation, it was 
hypothesized that GLS would be elevated in DRG neurons during chronic inflammation. 
GLS is a logical constituent of the glutamate-glutamine cycle to examine when 
considering increased glutamate levels since it is the enzyme that synthesizes 
neurotransmitter glutamate.  As mentioned previously for many other proteins expressed 
in the DRG, there is often disagreement among the reported distributions for a particular 
protein from different laboratories.  Such is also the case for GLS.  GLS activity was 
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identified in the DRG of rats and was shown to decrease by approximately 60% when 
70% of the DRG neurons where killed during development (McDougal, Yu et al. 1981).  
When only capsaicin sensitive neurons were killed during development, GLS activity 
decreased by 26% (McDougal, Yuan et al. 1983).  This indicated that the small diameter 
neurons expressed glutaminase, but were not the only DRG neurons to do so.  The first 
reports of GLS distribution by histological means indicated that 30% of small DRG 
neurons and no large DRG neurons expressed GLS (Cangro, Sweetnam et al. 1984; 
Cangro, Sweetnam et al. 1985).  A subsequent study determined that 40% of DRG 
neurons contained glutaminase, and they were all in the small cell population (Battaglia 
and Rustioni 1988).  In 1993, Miller et al. demonstrated GLS immunoreactivity in more 
than 80% of DRG neurons, irrespective of cell body size.  This was reiterated in another 
study where “almost all” DRG neurons were said to be immunoreactive for GLS (Li, 
Ohishi et al. 1996).  The difference between the former two and latter two studies can be 
accounted by the different fixatives used for perfusion.  The former studies, which 
reported lower estimates of GLS distribution, used a relatively high concentration (4% 
w/v) of the cross-linking fixative formaldehyde in their perfusates.  The latter studies, 
which reported more ubiquitous GLS distributions, used a concentration that was 20-fold 
lower (0.2% w/v) and added 1% (w/v) picric acid.  This phenomenon had been reported 
in a qualitative manner for neurons of the CNS (Kaneko, Itoh et al. 1989), although it has 
not been confirmed as to whether less formaldehyde or more picric acid is responsible for 
the increased sensitivity of GLS detection.  Optimization of fixation methods needs to be 
performed for accurate determination of GLS distribution in the DRG.  Such a protocol 
also should be applied for other proteins in the DRG for which there is no consensus on 
 12 
the exact distribution. Optimization of fixation, therefore, is the first project of this 
dissertation, prior to evaluation of GLS during inflammation.  
Nerve growth factor (NGF) 
Another inflammatory mediator with the ability to sensitize primary afferents is NGF.  
Recently, NGF antagonism has been suggested as a therapeutic approach for 
inflammatory pain (Hefti, Rosenthal et al. 2006; Watson, Allen et al. 2008).  Much of 
what is known about the effects of NGF on the peripheral nervous system comes from 
NGF deprivation studies.  Once NGF had been isolated and purified (Bocchini and 
Angeletti 1969), it was used to raise heterologous antibodies that were subsequently 
injected into animals.  Anti-NGF antibodies bind and prevent endogenous NGF from 
interacting with its targets.  Such experiments revealed that NGF deprivation during 
development resulted in loss of peripheral autonomic and sensory neurons (Levi-
Montalcini and Booker 1960).  If NGF was deprived in mature animals, only peripheral 
autonomic neurons were lost.  These experiments determined that all peripheral neurons 
rely on NGF for survival during development, but only peripheral autonomic neurons still 
have an NGF requirement for survival in adulthood.  The question as to what role, if any, 
NGF had in postnatal sensory neurons remained unanswered.  To help answer this 
question, a method of autoimmunization was developed wherein animals were actively 
immunized against NGF so that anti-NGF titers could be maintained chronically (Gorin 
and Johnson 1979).  This method allowed further characterization of chronic NGF 
deprivation in mature animals and confirmed that DRG neurons do not die or atrophy 
even after long term NGF deprivation (Gorin and Johnson 1980; Johnson, Gorin et al. 
1982; Schwartz, Pearson et al. 1982).    However, NGF immunized rats had delayed 
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withdrawal responses to noxious stimuli as measured by the hot plate test (Chudler, 
Anderson et al. 1997), which indicated a functional alteration of the small cell population 
of DRG neurons.  Injection of exogenous NGF can cause hyperalgesia in animals (Lewin, 
Ritter et al. 1993; Della Seta, de Acetis et al. 1994; Amann, Schuligoi et al. 1995) and 
humans (Dyck, Peroutka et al. 1997; Svensson, Cairns et al. 2003), and endogenous 
production of NGF increases during inflammation (Woolf, Safieh-Garabedian et al. 
1994).  Elevated levels of NGF sensitize primary afferents by both post-translational 
modification of pre-existing proteins and by increasing expression of proteins (Woolf, 
Safieh-Garabedian et al. 1994; Leslie, Emson et al. 1995; Schuligoi and Amann 1998; 
Gould, Gould et al. 2000; Ramer, Bradbury et al. 2001; Ji, Samad et al. 2002; Mamet, 
Lazdunski et al. 2003).  For this dissertation, it was hypothesized that normal expression 
of proteins important for nociception are dependent on basal NGF levels present in non-
inflamed tissue and depriving NGF would down-regulate expression of these proteins.  
Nav1.8 current density and mRNA levels are decreased in IB4 negative rat DRG neurons 
after NGF deprivation (Fjell, Cummins et al. 1999).  SP protein levels are decreased in 
the DRG, the dorsal horn of spinal cord and the skin after NGF deprivation (Schwartz, 
Pearson et al. 1982).  These are the only studies that document a decreased expression of 
pain-related proteins after long term NGF deprivation, and leave down-regulation of 
Nav
Neuronal expression of the proto-oncogene c-fos is rapidly and transiently elevated in 
response to stimulation.  Fos is the protein product of c-fos, and it forms heterodimeric 
complexes with other proteins in the Jun family that bind to the AP-1 target site on DNA 
1.8 and SP as the only explanation for hypoalgesia in NGF deprived animals. 
Fos expression in spinal cord 
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to regulate gene expression.  The function of Fos is, therefore, to link extracellular events 
to long-term cellular responses.  Noxious stimulation increases Fos expression in the 
dorsal horn of spinal cord where nociceptive DRG neurons of the ALS synapse (Hunt, 
Pini et al. 1987).  Since this initial discovery, spinal Fos expression, as measured by 
counting Fos-immunoreactive nuclei, has been used extensively to study cellular activity 
during noxious stimulation and quantify effects of various analgesics (Coggeshall 2005).  
Fos expression increases in dorsal horn after most types of noxious stimulation, but with 
varying degrees, localizations, temporal profiles, and susceptibility to analgesic 
suppression.   
One of the most commonly used and well characterized models is intraplantar 
injection of λ-carrageenan.  In response to carrageenan inflammation of the hind paw, Fos 
expression is rapidly elevated in the lumbar spinal cord dorsal horn (especially L4-L5) in 
superficial (I-II) and deep laminae (V-VI), peaks at 3 hours post injection, and is 
susceptible to suppression by central and peripheral analgesics (Honore, Buritova et al. 
1995; Coggeshall 2005).  Peripheral inhibition of cyclooxygenase (COX), the enzyme 
that makes prostaglandins, reduces Fos expression in dorsal horn during inflammation 
(Buritova and Besson 1998).  Since both prostaglandins and glutamate are implicated in 
nociceptor sensitization, measuring Fos expression in the dorsal horn would be a useful 
tool to study the analgesic potential of glutamate antagonism during inflammation.  As 
mentioned above, peripheral glutamate receptor antagonism attenuates hyperalgesia 
during inflammation, and decreased dorsal horn Fos expression corroborates these 
findings (Wang, Liu et al. 1997).  Since a previous study has shown that peripheral GLS 
inhibition has analgesic effects (Miller, Herzog et al. 2006), it would be interesting to 
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know if GLS inhibition can also reduce Fos expression during inflammation.  This was 
the fourth project of the current dissertation. 
Clinical problem of pain 
Chronic pain is medically managed with anti-inflammatory drugs, opioids, tricyclic 
antidepressants (TCAs), anticonvulsants, or any combination of these (Miller 2005).  
While many patients obtain relief from these treatments, there are cases of intractable and 
refractory pain that require high-risk interventional procedures.  In addition, there are 
many side effects of the aforementioned drugs because their molecular targets are widely 
expressed.  For instance, high doses of anti-inflammatory drugs can reach very high 
levels of pain relief, but can also precipitate gastrointestinal bleeding, renal failure, and 
congestive heart failure (McQuay and Moore 2005).  Another example would be the use 
of opioids for analgesia.  Opioids offer analgesic control over the most severe pain by 
inhibiting release of neurotransmitter from nociceptors and hyperpolarizing spinal cord 
neurons, but at the cost of affecting many other neurons in the CNS.  In addition to 
adverse effects of short-term opioid use such as constipation, nausea, and dysphoria, 
long-term adverse effects include psychological dependence, drug abuse, addiction, and 
physiological tolerance (Miller 2005).  Tricyclic antidepressants and anticonvulsants also 
are used as treatments for intractable pain.  The amine uptake inhibition of TCAs 
potentiates the effect of inhibitory neurotransmitters in the spinal cord and brain, but this 
most commonly leads to weakness and fatigue. TCAs also have relatively potent 
antimuscarinic effects that produce adverse autonomic disturbances.  Anticonvulsants 
block sodium and calcium channels, thereby decreasing excitation in activated pain 
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pathways, but also throughout the nervous system. This widespread decreased excitation 
can lead to dizziness, somnolence, ataxia, headache, blurred vision, and tremor. 
To avoid adverse side effects and provide treatment for problematic pain, novel 
analgesics should be directed at the neurons and sensitizing factors of the pain pathway.  
The TRPs (Patapoutian, Tate et al. 2009), Nav
Current analgesics cannot provide adequate pain relief for all individuals with chronic 
pain, and they have many adverse effects that prohibit prescribing long-term high doses.  
New therapeutic options, therefore, are needed for management of chronic pain.  Neurons 
in the DRG that are part of the “pain pathway” present a useful target for design of novel 
analgesics since they are at the beginning of the pathway.  If their sensitization can be 
prevented or inhibited, then the burden of pain on the patient will be lessened.  In order to 
identify potential molecular targets in these cells, more detailed characterization of 
nociceptive DRG neuron populations is necessary.  In general, small diameter DRG 
neurons with thin, lightly myelinated or unmyelinated axons that synapse in the dorsal 
horn of spinal cord bring nociceptive information into the CNS.  The two most widely 
accepted nociceptor populations are peptidergic and nonpeptidergic based on their ability 
s (Kort, Drizin et al. 2008), and NGF 
(Hefti, Rosenthal et al. 2006) have been suggested as targets for analgesic development 
since they have a somewhat limited distribution and have been shown to be integral to 
sensitization of nociceptors.  Peripheral glutamate antagonism also has been suggested 
for analgesic development (Carlton 2001).  While glutamate is the most common 
neurotransmitter used at CNS synapses, specific peripheral inhibition at the site of 
inflammation may provide a novel analgesic strategy that would have few central effects. 
Summary 
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to release the peptides SP and CGRP.  Identifying the exact distribution of molecular 
markers among DRG neurons is crucial for development of new analgesics.  However, 
there are inconsistencies with current estimates of marker distribution among studies, 
indicating the need for optimization and standardization of the protocol for 
determining DRG neuron populations (Chapter 2). 
Much evidence indicates that all DRG neurons use the neurotransmitter glutamate for 
release at synapses within the CNS, and it is strongly implicated in autostimulation of the 
peripheral terminal as well.  However, the distribution of GLS, the glutamate 
synthesizing enzyme, is not clear and needs to be determined (Chapter 2).  Glutamate is 
a sensitizer of both the peripheral terminal and dorsal horn neurons.  Levels of glutamate 
increase in inflamed tissues and spinal cord dorsal horn, and the source may be primary 
afferent neurons in both cases.  GLS is, therefore, a potential analgesic target.  During 
sensitization, DRG neurons increase expression of proteins important for nociception, 
and it is important to know if GLS is among the proteins up-regulated during 
sensitization (Chapter 3). 
Nerve growth factor, the inflammatory mediator and primary afferent sensitizer, is 
thought to be involved not only in the increased expression of proteins in DRG neurons 
during sensitization, but also in determining the basal expression of these proteins.  
Deprivation of NGF by autoimmunization has been used as a way to study the effects of 
NGF on DRG and peripheral autonomic neurons.  Autoimmunization produces 
hypoalgesia in rats, but it is not known if decreased glutamate availability is included in 
the mechanism.  It would be advantageous to know if basal expression of GLS is 
regulated by peripheral NGF levels (Chapter 4). 
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Antagonism of glutamate receptors at the periphery during inflammation provides 
analgesia.  If GLS is responsible for elevated glutamate levels produced during 
inflammation, then peripheral GLS inhibition may be a viable pain therapy.  Glutamate 
receptor antagonism (Wang, Liu et al. 1997) at the periphery can decrease expression of 
Fos in the spinal cord during inflammation, implicating suppression of sensitization and 
hyperalgesia.  In order to substantiate GLS as a novel therapeutic target for 
inflammatory pain, the ability of peripheral GLS inhibition to suppress spinal Fos 










Figure 1.1. Schematic representation of the spinal circuitry for the two primary 
somatosensory systems modified from Haines 2005.  The anterolateral system (ALS) is 
represented on the left and the posterior column-medial lemniscal (PCML) system is 
represented on the right.  The ALS primarily conveys sensory information regarding pain, 
temperature and crude touch.  The PCML pathway primarily conveys light touch, 
proprioception and vibration sensory information.  C-fibers are unmyelinated, whereas A 
fibers are myelinated.  However, the Aδ fibers are more lightly myelinated than Aα/β 
fibers.  C-fibers terminate as bare nerve endings that have membrane proteins specific to 
nociceptive stimuli (Haines 2005). 
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Figure 1.2.  Frequency distribution relating cell size with cell number.  Two populations 
are apparent as demonstrated by two computer-identified normal distributions.  The small 
cell population (……) is tall and narrow, while the large cell population (·-·-·-·-·-) is short 










Figure 1.3. Schematic view of the glutamate-glutamine cycle between DRG neurons and 
their glia.  Released glutamate (glu) is transported into neurons and glia by excitatory 
amino acid transporter 3 (EAAT3) and EAAT1, respectively.  Satellite glial cells and 
Schwann cells convert glutamate to glutamine (gln) with the enzyme glutamine 
synthetase (GS).  Glutamine is transported back to neurons by sodium-coupled neutral 
amino acid transporters (SNATs) where it is converted to glutamate by the enzyme 
glutaminase (GLS).  Glutamate is packaged into synaptic vesicles by vesicular glutamate 
transporters (VGLUTs).  A DRG neuron is represented in green, glia in blue, post-





Determination of glutaminase distribution in the rat dorsal root ganglion and 
optimization of immunofluorescence methods 
Abstract 
 Identification of populations and subpopulations of dorsal root ganglion neurons 
is commonly accomplished with immunofluorescence and immunohistochemical 
techniques that rely on the specific interaction between antigen and antibody.  In addition 
to the variable binding affinities and kinetics of certain antibodies and antisera raised 
against antigens, mode and length of fixation influences antigen-antibody interactions.  
Although antibody dilution and incubation length are routinely optimized during 
technique development, the results are rarely analyzed and discussed.  Occasionally, 
different methods or lengths of fixation are examined, but the effect of individual fixative 
components on immunoreactivity has not been systematically examined with quantitative 
image analysis methods.  Proper characterization of DRG neuron populations relies on 
robust detection of antigen.  In this study, we compared five concentrations of 
formaldehyde (4%, 2%, 1%, 0.5%, and 0.25% w/v) and five concentrations of picric acid 
(0.8%, 0.4%, 0.2%, 0.1%, and 0.0%) on immunoreactivity (IR) for glutaminase, voltage 
gated sodium channel Nav1.8, and the capsaicin receptor TRPV1.  In addition, we 
demonstrated the effect of incubation length in primary antiserum on IR.  Decreasing 
formaldehyde concentration led to an increase in glutaminase- and TRPV1-IR, while
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increasing picric acid concentration led to an increase in Nav1.8-IR.  Increasing IR has 
the net effect of improving detection sensitivity and leads to wider definitions of DRG 
neuron populations.  By selecting fixation conditions that optimize IR, our results for 
glutaminase, Nav
Immunohistochemical and immunofluorescence methods have been essential in 
identifying putative neurotransmitters for specific neurons throughout the central and 
peripheral nervous systems.  Glutamate is widely accepted as the major excitatory 
neurotransmitter of the central nervous system and is a candidate for use by 
pseudounipolar primary sensory neurons at all central terminals (Skilling, Smullin et al. 
1988; De Biasi and Rustioni 1990; Zahn, Sluka et al. 2002; Li, Fujiyama et al. 2003; 
Dmitrieva, Rodriguez-Malaver et al. 2004; Brumovsky, Watanabe et al. 2007) and at 
some peripheral terminals (deGroot, Zhou et al. 2000; Jin, Nishioka et al. 2006; 
Brumovsky, Watanabe et al. 2007).  One marker of glutamatergic function is the enzyme 
glutaminase (GLS; EC 3.5.1.2), which synthesizes glutamate from glutamine.  However, 
based on GLS-immunoreactivity (IR), there is inconsistency between the estimated 
percentages of glutamatergic peripheral sensory neurons ranging from approximately 
30%-40% of the small cell population in the rat dorsal root ganglion (DRG) (Cangro, 
Sweetnam et al. 1984; Cangro, Sweetnam et al. 1985; Battaglia and Rustioni 1988) to 
greater than 80% of all DRG cells (Miller, Douglas et al. 1993; Li, Ohishi et al. 1996).  
One difference between these DRG studies is the fixative used for tissue preservation.  
GLS-IR in brain neurons diminishes as formaldehyde concentration in the fixative 
1.8, and TRPV1 concur with other methods of investigating these 
neuronal populations.  
Introduction 
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increases from 0.2% to 4% (w/v) (Kaneko, Itoh et al. 1989); therefore, a similar 
phenomenon may occur in the DRG.  Picric acid concentration in the fixative also 
differed among studies of GLS-IR as well as length of incubation in the primary 
antiserum.  
In the present study, we compared the effects of formaldehyde and picric acid 
concentrations in the fixative as well as length of incubation in primary antiserum for 
immunofluorescence studies of GLS, voltage-gated sodium channel 1.8 (Nav
Sprague-Dawley rats (n = 13; 200-300 g) were housed on a 12 hour light: 12 hour 
dark cycle and given free access to food and water.  Procedures were conducted 
according to guidelines from the National Institutes of Health (NIH 2003) and were 
approved by the Oklahoma State University Center for Health Sciences Institutional 
1.8), and 
transient receptor potential vanilloid receptor 1 (TRPV1) in rat DRG.  
Electrophysiological properties, axon diameters, and cell body sizes have been used in 
attempts to classify populations of DRG neurons (Yoshida and Matsuda 1979; Lee, 
Chung et al. 1986; Fang, McMullan et al. 2005).  More recently, protein markers have 
been used to identify subpopulations of some modalities, like TRPV1 for painful heat 
(Caterina, Schumacher et al. 1997).  However, as with GLS, the reported percentages of 
DRG neurons expressing specific markers have varied, thus hindering a firm 
classification schema from being adopted.  We propose that rigorous optimization of 
tissue preparation, including fixation, for each antigen should take place to determine its 
true distribution and relative abundance in DRG neurons. 
Methods 
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Animal Care and Use Committee.  All appropriate efforts were made to minimize the 
number of animals used in this study. 
Rats were anesthetized with Avertin (2.5% w/v) and xylazine and then perfused 
through the ascending aorta with 75 mL calcium-free Tyrode’s solution, pH 7.3 followed 
by 300 mL fixative.  Five rats were used for the formaldehyde comparison. The fixative 
used for each rat contained 0.2% (w/v) picric acid, 0.1 M sodium phosphate buffer, and 
was adjusted to pH 7.3.  Formaldehyde concentration was varied among the five fixatives 
to contain 4%, 2%, 1%, 0.5%, or 0.25% (w/v).  Five rats were used for the picric acid 
comparison.  The fixative used for each rat contained 1.0% (w/v) formaldehyde, 0.1 M 
sodium phosphate buffer, and was adjusted to pH 7.3.  Picric acid concentration was 
varied among the five fixatives to contain 0.8%, 0.4%, 0.2%, 0.1%, or 0.0% (w/v).  Two 
additional rats were used for the primary antisera incubation time comparison.  The 
fixative used for both animals was 0.2% picric acid and 1.0% formaldehyde in 0.1 M 
sodium phosphate buffer adjusted to pH 7.3.  Left and right L4 DRG were dissected from 
perfused rats.  DRG from each rat were post-fixed for four hours at 4°C in the same 
fixative used for perfusion and then were cryoprotected overnight at 4°C in phosphate 
buffered saline, pH 7.3 (PBS) containing 10% (w/v) sucrose.   
All DRG for a given comparison (i.e., formaldehyde, picric acid, primary incubation 
time) were embedded into one frozen block and cut in 8 µm serial sections on a Microm 
HM 550 OMVP cryostat (Richard Allan Scientific; Kalamazoo, MI).  To prevent 
recounting of neurons for a given primary antiserum, sections were allotted in order to 
one of the three antisera and the fourth section was discarded each time, making the 
minimum approximate distance between two analyzed sections 24 µm.  Sections were 
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thaw-mounted to gelatin-coated SuperFrost slides (Fisher Scientific; Pittsburg, PA, USA) 
and dried for two hours at 37°C.  Dried sections were rinsed three times in PBS before 
blocking for one hour at room temperature in 5% (v/v) normal goat serum, 1% (w/v) 
bovine serum albumin, and 1% (w/v) polyvinylpyrollidone (PVP) in PBS with 0.2% (v/v) 
Triton X-100 (PBS-T).  Sections for the formaldehyde and picric acid comparisons were 
incubated in primary antisera diluted with PBS-T for four days at 4°C.  Sections for the 
primary incubation time comparison were incubated at room temperature for two hours or 
at 4°C for 20, 48, 96, or 192 hours.  For GLS detection, polyclonal rabbit antiserum 
against whole GLS made by N.P. Curthoys (Colorado State University; Ft. Collins, CO) 
was used at 1:10,000.  For Nav1.8 detection, polyclonal rabbit antiserum (Sigma; 
St.Louis, MO) against a 15 amino acid peptide corresponding to the C-terminal residues 
(EDEVAAKEGNSPGPQ) of rat Nav1.8 was used at 1:2,000.  For TRPV1 detection, 
polyclonal guinea pig antiserum (Neuromics; Edina, MN) against a 22 amino acid 
peptide corresponding to the C-terminal residues (YTGSLKPEDAEVFKDSMVPGEK) 
of rat TRPV1 was used at 1:2,000.  Following incubation in primary antiserum, sections 
were rinsed three times in PBS and incubated in secondary antibody diluted in PBS-T at 
1.0 µg/mL for one hour at room temperature.  For detection of rabbit anti-GLS antiserum 
or rabbit anti-Nav1.8 antiserum, biotinylated goat anti-rabbit (Vector Laboratories; 
Burlingame, CA) antiserum was used.  For detection of guinea pig anti-TRPV1 
antiserum, AlexaFluor 488 conjugated goat anti-guinea pig (Molecular Probes; Carlsbad, 
CA) antiserum was used. GLS and Nav1.8 sections were rinsed two more times in PBS, 
once in sodium carbonate buffered saline, pH 9.0 (SCBS), and then incubated for one 
hour at room temperature in 1.0 µg/mL fluorescein-conjugated avidin D (Vector 
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Laboratories) diluted in SCBS.  All sections were rinsed three more times in PBS and 
coverslipped with ProLong Gold (Molecular Probes).   
Primary antiserum absorption control and secondary antiserum control experiments 
were performed for the three primary antisera and two secondary antisera, respectively.  
An additional rat was perfused with 0.8% picric acid and 0.25% formaldehyde, 
concentrations that gave the highest immunofluorescence.  For primary absorption 
controls, each diluted antiserum was incubated for 24 hours at 4°C with the respective 
antigen at 10-40 µg/mL.  Adjacent sections were incubated for four days at 4°C in either 
absorbed diluted antisera or non-absorbed antisera.  The secondary controls sections were 
incubated in antiserum diluents only for four days at 4°C prior to routine processing. 
Images were acquired using the 20X objective on an Olympus BX51 epifluorescence 
microscope (Olympus; Center Valley, PA, USA) equipped with a SPOT RT740 
monochrome camera (Diagnostic Instruments; Sterling Heights, MI, USA).  To ensure 
proper quantitation, all images were captured at a bit-depth of 8 using a 300 millisecond 
exposure with the gain set at 1.  Captured images were 1600 × 1200 pixels with 2.69 
pixels per micrometer.  For the formaldehyde and picric acid comparisons, three slides 
for each antiserum were used and three images from each of the five treatments were 
captured, making 45 images per antiserum and 135 images per fixative comparison.  For 
the primary antibody incubation comparison, two slides for each antiserum for each of 
the five time points were used and four images from each slide, making 40 images per 
antiserum.  All neuron profiles with a visible nucleus that were not touching the edge of 
the image were traced on a Cintiq 21UX interactive pen display (Wacom; Kita Saitama-
Gun, Saitama, Japan) using the freehand selections tool in ImageJ (NIH).  Nuclei were 
 28 
excluded from the regions of interest (ROIs), making each ROI correspond to the 
cytoplasmic profile of a single DRG neuron.  Pixel intensities could range from 0 
(darkest) to 255 (lightest) on a grayscale.  The mean gray value and area in m 2 for each 
cytoplasmic profile was measured and copied to a spreadsheet. 
Data were analyzed with Prism v5.01 (GraphPad Software; San Diego, CA).  The 
mean gray values for each cell were converted to Relative Immunoreactivity by using the 
following formula [(MAX – mean gray value)/(MAX – MIN)] × 100, where MAX and 
MIN are the maximum and minimum mean gray values for cytoplasmic profiles in a 
given comparison of experimental conditions with one of the three antisera.  Scatter plots 
were made where the cytoplasmic profile area was plotted as cell size (m2) on the x-
axis and the relative immunoreactivity (ranging from 0 to 100) was plotted on the y-axis.  
For subsequent calculations, the values for area (µm2) of the cytoplasmic profile were 
binned into small (<600 µm2) and large (>600 µm2
A total of 3115 cytoplasmic profiles were traced and analyzed for the formaldehyde 
comparison.  The number of cytoplasmic profiles analyzed per condition (three antisera × 
) size categories to indicate two 
broadly defined neuronal subpopulations.  All data are represented as mean ± SD.  
Significant differences in mean relative immunoreactivities for small and large cells 
among different experimental conditions were determined by two-way ANOVA with 
Bonferroni post-tests.  Correlation and linear regression analyses were done by plotting 
the experimental condition that was varied on the x-axis and the relative 
immunoreactivity on the y-axis with small and large cell values representing separate 
data sets.  Results were considered significant when P < 0.05. 
Results 
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five formaldehyde concentrations = 15 conditions) was 208 ± 43.  The numbers of 
cytoplasmic profiles traced and analyzed for GLS, Nav1.8, and TRPV1 were 1103, 1232, 
and 780, respectively.   
The effect of formaldehyde on GLS-IR was qualitatively apparent from images 
(Figure 2.1A-E) or the scatter plot (Figure 2.2A) and is reminiscent of the effects noted in 
brain neurons (Kaneko, Itoh et al. 1989).  Decreasing the fixative formaldehyde 
concentration from 4% (commonly used) to 2% or lower significantly increased GLS-IR 
for both small and large cells (Figure 2.3A).  There was a significant negative correlation 
between formaldehyde concentration and GLS-IR (Figure 2.4A) between both small (P < 
0.0001) and large cells (P < 0.0001).  Linear regression analyses determined the slopes 
and y-intercepts of the lines to be -9.794 ± 0.2905 and 58.47 ± 0.6289 (r2 = 0.6159) for 
the small cells and -10.88 ± 0.4045 and 51.64 ± 0.8149 (r2
To see if the effects of formaldehyde concentration in the fixative were specific to 
GLS-IR, we examined Na
 = 0.6498) for the large cells 
(Figure 2.4A).  Therefore, as formaldehyde concentration increased, GLS-IR decreased, 
and 62-65% of the variation in GLS-IR can be explained by variation in formaldehyde 
concentration.  The magnitude of this effect on small and large cells was estimated by the 
slope of the linear regression lines, which showed that the effect was significantly greater 
on large cells (P = 0.034).  Also, as seen in the images (Figure 2.1A), scatter plots (Figure 
2.2A), and means plots (Figure 2.3A), small cells consistently have higher GLS-IR than 
large cells.  This is recapitulated by the y-intercept values from the regression lines 
(Figure 2.4A).  It is not possible to test whether the y-intercepts differ significantly, 
because the slopes are significantly different. 
v1.8-IR and TRPV1-IR in DRG sections from the same rats.  
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Qualitatively, the effect of formaldehyde on IR for these two proteins (Figure 2.1F-J and 
2.1K-O) was not as apparent as it was for GLS (Figure 2.1A-E).  Quantitative image 
analysis, however, revealed that lowering the formaldehyde concentration to 2% and 
lower led to significant increase in Nav1.8-IR of small cells, whereas it had to be lowered 
all the way to 0.25% in order to show a significant increase in Nav1.8-IR of large cells 
(Figure 2.3B).  Similarly, lowering the formaldehyde concentration to 1% and lower led 
to a significant increase in TRPV1-IR of small cells, whereas it had to be lowered to 
0.5% in order to show a significant increase in TRPV1-IR of large cells (Figure 2.3C).  
Negative correlations between formaldehyde concentration and Nav1.8-IR (Figure 2.4B) 
were significant for small (P < 0.0001) and large cells (P = 0.0142).  The slopes and y-
intercepts were -2.342 ± 0.3510 and 36.57 ± 0.6792 (r2 = 0.05166) for small cells and -
1.204 ± 0.4890 and 21.46 ± 1.082 (r2 = 0.1454) for large cells (Figure 2.4B).  Negative 
correlations between formaldehyde and TRPV1-IR (Figure 2.4C) were significant for 
small (P < 0.0001) and large cells (P < 0.0001).  The slopes and y-intercepts were -4.250 
± 0.4322 and 29.77 ± 0.8025 (r2 = 0.1496) for small cells and -1.747 ± 0.2705 and 15.83 
± 0.6168 (r2 = 0.1558) for large cells (Figure 2.4C).  Therefore, the magnitude of the 
effect of formaldehyde concentration on Nav1.8-IR and TRPV1-IR is less than on GLS-
IR, as evidenced by the slopes.  Moreover, the effect on Nav1.8-IR is not significantly 
different between small and large cells while it is significantly different (P < 0.001) for 
TRPV1-IR.  Since the slopes did not differ for Nav1.8, it was possible to determine that 
the difference was significantly different (P < 0.0001) between the y-intercepts, 
indicating that small cells consistently had higher Nav1.8-IR.  Even though it could not 
be determined statistically in the linear regression model, qualitative assessment of 
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images (Figure 2.1C) in addition to evaluation of the means indicated that small cells had 
higher TRPV1-IR than large cells.  
A total of 2955 cytoplasmic profiles were traced and analyzed for the picric acid 
comparison.  The number of cytoplasmic profiles analyzed per condition (three antisera × 
five picric acid concentrations = 15 conditions) was 197 ± 41.  The numbers of 
cytoplasmic profiles traced and analyzed for GLS, Nav1.8, and TRPV1 were 935, 993, 
and 1027, respectively. 
The effect of picric acid on GLS-IR was not qualitatively apparent from images 
(Figure 2.5A-E) or the scatter plot (Figure 2.2B).  Adding any amount of picric acid in 
the fixative did not significantly increase the mean immunoreactivity for either small or 
large cells (Figure 2.6A).  There was no significant correlation between picric acid 
concentration and GLS-IR (Figure 2.7A) between either small (P = 0.8306) or large cells 
(P = 0.5251).  Linear regression analyses determined the slopes and y-intercepts of the 
lines to be 0.5816 ± 2.717 and 45.14 ± 1.163 (r2 = 0.00008392) for the small cells and 
2.184 ± 3.434 and 31.31 ± 1.355 (r2 = 0.001050) for the large cells (Figure 2.8A).  
Therefore, picric acid concentration did not affect GLS-IR because only 0.008% to 0.1% 
of the variation in GLS-IR can be explained by variation in picric acid concentration.  
Even though there was no picric acid effect on GLS-IR, there was still a cell size effect 
on GLS-IR as seen in the images (Figure 2.5A-E), scatter plot (Figure 2.2B), and means 
plots (Figure 2.6A) where small cells consistently had higher GLS-IR than large cells.  
This is recapitulated by the y-intercept values from the regression lines (Figure 2.7A).  
Since the slopes for the small and large cells were not significantly different (P = 0.71), it 
was possible to show that the y-intercepts differed significantly (P < 0.0001).  
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To determine if the picric acid concentration in the fixative had effects on IR for 
proteins other than GLS, we examined Nav1.8-IR and TRPV1-IR in DRG sections from 
the same rats.  Qualitatively, the effect of picric acid on IR for these two proteins was 
more apparent than it was for GLS (Figure 2.5F-O).  Quantitative image analysis 
revealed that raising the picric acid concentration to 0.2% and higher led to significant 
increase in Nav1.8-IR of small cells, whereas adding any amount of picric acid did not 
show a significant increase in Nav1.8-IR of large cells (Figure 2.6B).  The only 
significant difference in Nav1.8-IR among large cells was a slight decrease when 0.4% 
was used.  Adding any amount of picric acid led to a significant increase in TRPV1-IR of 
small cells, whereas it had to be increased to 0.8% (w/v) in order to show a significant 
increase in TRPV1-IR of large cells (Figure 2.6C).  Positive correlations between picric 
acid concentration and Nav1.8-IR (Figure 2.7B) were significant for small (P < 0.0001) 
but not large cells (P = 0.9198).  The slopes and y-intercepts were 25.40 ± 2.237 and 
27.70 ± 0.9834 (r2 = 0.1939) for small cells and 0.3161 ± 3.139 and 23.87 ± 1.182 (r2 = 
0.00002238) for large cells (Figure 2.7B).  Positive correlations between picric acid and 
TRPV1-IR (Figure 2.7C) were significant for small (P < 0.0001) and large cells (P < 
0.0001).  The slopes and y-intercepts were 10.10 ± 2.015 and 24.33 ± 0.9458 (r2 = 
0.03821) for small cells and 7.151 ± 1.441 and 12.48 ± 0.5939 (r2 = 0.05921) for large 
cells (Figure 2.7C).  There was, therefore, an effect of picric acid concentration on 
Nav1.8-IR in small cells but not on large cells and the magnitude of the effect of picric 
acid concentration on TRPV1-IR was not significantly different on small and large cells 
(P = 0.31).  Since the slopes did not differ for TRPV1-IR, it was possible to determine 
that the difference was significant (P < 0.0001) between the y-intercepts, indicating that 
 33 
small cells consistently had higher TRPV1-IR.  Even though it could not be determined 
statistically in the linear regression model, qualitative assessment of images (Figure 2.5F-
J), in addition to evaluation of the means (Figure 2.6B), indicated that small cells had 
higher Nav1.8-IR than large cells. 
A total of 2838 cytoplasmic profiles were traced and analyzed for the incubation 
length comparison.  The number of cytoplasmic profiles analyzed per condition (three 
antisera × five incubation lengths = 15 conditions) was 189 ± 35.  The numbers of 
cytoplasmic profiles traced and analyzed for GLS, Nav
The effect of incubation length on GLS-IR was qualitatively apparent from images 
(Figure 2.8A-E) and the scatter plot (Figure 2.2C).  Quantitative analysis (Figure 2.9A) 
revealed that incubating for 20-48 hours increased GLS-IR significantly compared to just 
two hours of incubation (P < 0.0001); however, there was no significant difference 
between incubating for 24 versus 48 hours.  Moreover, incubating for 96 to 192 hours 
further increased GLS-IR above 24-48 hours of incubation (P < 0.0001).  The longest 
incubation of 192 hours did not yield higher GLS-IR than 96 hours.  Significant 
differences among incubation lengths, or lack thereof, were similar between small and 
large cells.  There was significant correlation between primary antiserum incubation 
length and GLS-IR (Figure 2.10A) between both small (P < 0.0001) and large cells (P < 
0.0001).  Linear regression analyses determined the slopes and y-intercepts of the lines to 
be 0.1588 ± 0.8251 and 25.11 ± 0.8251 (r
1.8, and TRPV1 were 1012, 1002, 
and 824, respectively. 
2 = 0.3661) for the small cells and 0.1760 ± 
0.01005 and 17.46 ± 0.9370 (r2 = 0.4454) for the large cells (Figure 2.10A).  Therefore, 
increasing incubation length increased GLS-IR, and approximately 37 to 45% of the 
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variation in GLS-IR can be explained by variation in incubation length.  The magnitude 
of this effect on small and large cells was estimated by the slope of the linear regression 
lines, which showed that the effect was not significantly different between cell sizes (P = 
0.21; Figure 2.10A).  Also, as seen in the images (Figure 2.8A-E), scatter plots (Figure 
2.2C), and means plots (Figure 2.9A), small cells consistently have higher GLS-IR than 
large cells.  This is recapitulated by the y-intercept values from the regression lines 
(Figure 2.10A).  Since the slopes were not significantly different, it was possible to show 
that the y-intercepts differed significantly (P < 0.0001). 
To see if the effects of incubation length in primary antiserum were specific to GLS-
IR, we examined Nav1.8-IR and TRPV1-IR in DRG sections from the same rats.  
Qualitatively, the effect of incubation length on IR for these two proteins (Figure 2.8F-O) 
was apparent after at least 48 hours of incubation.  However, quantitative image analysis 
(Figure 2.9B) revealed that a significant increase in Nav1.8-IR of small cells occurred 
between 2 and 20 hours (P < 0.0001).  Increasing incubation length continued to increase 
Nav1.8-IR up to 192 hours, with the exception that there was no significant difference 
between 48 and 96 hours of incubation.  For large cells, Nav1.8-IR was not significantly 
different between 48, 96, and 192 hours of incubation.  Results were similar for TRPV1-
IR (Figure 2.9C) in that quantitative differences were noted as early as 20 hours of 
incubation, while there were no significant differences between 96 and 192 hours of 
incubation for either small or large cells.  Positive correlations between incubation length 
and Nav1.8-IR (Figure 2.10B) were significant for small (P < 0.0001) and large cells (P < 
0.0001).  The slopes and y-intercepts were 0.1673 ± 0.009206 and 27.23 ± 0.8734 (r2 = 
0.3397) for small cells and 0.08559 ± 0.01290 and 19.49 ± 1.296 (r2 = 0.1100) for large 
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cells (Figure 2.10B).  Positive correlations between incubation length and TRPV1-IR 
(Figure 2.10C) were significant for small (P < 0.0001) and large cells (P < 0.0001).  The 
slopes and y-intercepts were 0.09434 ± 0.006352 and 19.11 ± 0.6532 (r2 = 0.2735) for 
small cells and 0.07518 ± 0.008109 and 13.74 ± 0.6708 (r2 = 0.2686) for large cells 
(Figure 2.10C).  The magnitude of the effect of incubation length on Nav
In the present study, we sought to clarify the extent of GLS expression among rat 
DRG neurons and determine the effects of fixative composition and incubation length on 
IR for GLS, Na
1.8-IR was 
significantly different (P < 0.0001) between small and large cells, whereas it was not for 
TRPV1-IR (P = 0.13).  Since the slopes were not different for TRPV1-IR between small 
and large cells, it was possible to show that the y-intercept was significantly higher for 
small cells (P < 0.0001), which is consistent with previous comparisons. 
 Absorbing each of the three antisera with antigen diminished IR to near 
background levels (Figure 2.12, top three rows).  In addition, omitting primary antisera 
resulted in no IR (Figure 2.12, bottom row).  Control experiments indicate that the 
primary antisera used were specific for their respective antigens and the secondary 
antisera used produced little to no nonspecific labeling.  These control experiments were 
effective at optimal or near optimal fixative concentrations and incubation lengths.  
Discussion 
v1.8, and TRPV1.  Previous studies showed a broad range in the 
percentage of rat DRG neurons exhibiting GLS-IR (Cangro, Sweetnam et al. 1984; 
Cangro, Sweetnam et al. 1985; Miller, Douglas et al. 1993; Li, Ohishi et al. 1996), which 
we attributed to the difference in formaldehyde concentration in the fixative used for 
tissue preservation (Kaneko, Itoh et al. 1989).  We therefore hypothesized a negative 
 36 
correlation between GLS-IR and formaldehyde concentration.  By performing a two-fold 
dilution curve of formaldehyde concentration in fixative, we were able show this 
correlation qualitatively (Figure 2.1A-E).  In addition, we obtained quantitative measures 
of GLS-IR of the cytoplasm in combination with size measurements for each neuron 
(Figure 2.2A).  Statistical analysis of these data revealed significant elevations in GLS-IR 
as formaldehyde concentration decreased (Figure 2.3A).  Furthermore, a statistically 
significant negative correlation was found to be present in the quantitative data, as 
hypothesized (Figure 2.4A).  Picric acid is another fixative component used in the studies 
that reported higher estimates of GLS expression in the rat DRG, so we also compared 
the effects of five concentrations of picric acid on GLS-IR.  Our results indicate that 
picric acid has no effect on GLS-IR (for the polyclonal anti-GLS used in this study), and 
we presume the reported differences in GLS expression were primarily due to effects of 
formaldehyde concentration in the fixative.     
Estimating percentages of DRG neurons labeling for a specific antigen is typically 
performed by qualitatively scoring images to obtain counts of labeled and unlabeled 
neurons.  The qualitative score is assigned based on the investigator’s opinion of the 
staining intensity/quality relative to background IR levels.  The simplest and closest way 
to quantitatively approximate this type of scoring is to set an intensity threshold, above 
which neurons are considered labeled, and below which they are considered unlabeled.  
The threshold must be set by the investigator in a manner similar to qualitative scoring by 
viewing many images from a data set and determining an intensity that best distinguishes 
labeled from unlabeled neurons.  When such a practice was carried out for GLS-IR in our 
formaldehyde comparison, we estimated that 38% of all neurons had GLS-IR above the 
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chosen threshold when using 4% formaldehyde in the fixative (Figure 2.11A).  Using the 
same threshold, this estimate changed to 100% when 1% or less formaldehyde was used 
(Figure 2.11B).  The quality of GLS-IR (i.e. punctuate “mitochondrial” staining) 
indicated that the IR most likely was specific for GLS and, therefore, sensitivity was 
increasing as formaldehyde concentration decreased.  Background fluorescence did not 
increase appreciably, indicating that loss of specificity did not account for the higher 
estimates of GLS expression.  Expression of GLS in all DRG neurons is consistent with 
the need of all DRG neurons to have a means to synthesize neurotransmitter glutamate at 
their central terminals (Skilling, Smullin et al. 1988; De Biasi and Rustioni 1990; Zahn, 
Sluka et al. 2002; Li, Xiong et al. 2003; Dmitrieva, Rodriguez-Malaver et al. 2004; 
Brumovsky, Watanabe et al. 2007).  The higher GLS-IR of small DRG neurons may 
correspond to the added ability of small diameter nociceptive DRG neurons to release 
glutamate from their peripheral terminals (deGroot, Zhou et al. 2000; Jin, Nishioka et al. 
2006; Brumovsky, Watanabe et al. 2007). 
Similar, albeit less pronounced, effects were seen for Nav1.8 and TRPV1, indicating 
that the effect of fixation on IR is not specific to GLS.  For Nav1.8, however, picric acid 
had the largest effect on IR.  As higher concentrations of picric acid were used in the 
fixative, Nav1.8-IR increased.  The percentages of DRG neurons labeling for Nav1.8 
were 53% and 69% using 0% and 0.8% picric acid, respectively (Figure 2.11C and D).  
Interestingly, the effect of picric acid seemed to be specific for DRG neurons under 600 
µm2 (Figure 2.6B and 2.7B) since Nav1.8-IR of larger neurons was not consistently 
increased by picric acid concentration (Figure 2.6B and 2.7B).  According to another 
study using immunofluorescence that fixed with 4% formaldehyde and 0.0% picric acid, 
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approximately 50% of adult rat DRG neurons express Nav1.8 (Benn, Costigan et al. 
2001).  Although there have been no studies of Nav1.8-IR where 0.8% picric acid has 
been used to fix rat DRG, in-situ hybridization for Nav1.8 has shown that 66.5-68.9% of 
DRG neurons express Nav
The antigen masking properties of formaldehyde have been well documented 
(Sompuram, Vani et al. 2004) and many antigen retrieval techniques have been 
developed in order to restore epitope-antibody interactions that are hindered by aldehyde 
1.8 mRNA (Fukuoka, Kobayashi et al. 2008). 
TRPV1-IR was affected by both formaldehyde and picric acid concentration.  
Decreasing formaldehyde and increasing picric acid elevated TRPV1-IR.  The effect of 
formaldehyde was greater in this study than that of picric acid.  The effect of picric acid, 
however, may have been greater if the formaldehyde concentration used for the picric 
acid comparison was lower than 1%.  To prevent morphological changes to the tissue 
caused by inadequate fixation, we chose to include 1% formaldehyde in all of the picric 
acid comparisons.  The percentages of DRG neurons labeling for TRPV1 were 25% and 
70% using 4% and 0.25% formaldehyde, respectively (Figure 2.11E and F).  Background 
IR levels were not appreciably different when using different concentrations of 
formaldehyde and picric acid suggesting that lowering formaldehyde or increasing picric 
acid is not resulting in a sacrifice in specificity.  We suggest that TRPV1 expression has 
been underestimated previously by using a high concentration (4%) of formaldehyde in 
the fixative.  One study noted that 25% of primary sensory neurons had TRPV1-IR, 
however, in the same study 65% of DRG neurons responded to the TRPV1 agonist 
capsaicin with calcium imaging.  These estimates are close to our results of 25% and 70% 
with 4% and 0.25% formaldehyde, respectively. 
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mediated changes of the tissue (Shi, Key et al. 1991; Shi, Cote et al. 2001; Shi, Liu et al. 
2007).  Antigen retrieval is empirical by nature.  There is no guarantee that 100% 
retrieval will be accomplished even when all incubation solutions and temperatures have 
been attempted.  For clinical pathology labs, antigen retrieval is sometimes the only 
option, as the standard fixative (formalin) is close to the 4% formaldehyde used in many 
research laboratories and taking another sample for the purpose of fixing it differently is 
not always an option.  However, basic research is not limited by the same standard 
fixation protocol.  The results of our study suggest optimizing the fixation step so that 
antigen retrieval is unnecessary. 
In addition to fixation conditions, it is also necessary to optimize incubation length in 
immunoreagents to obtain a clear picture concerning the distribution and relative amount 
of antigen in DRG neurons.  The incubation length comparison revealed increased IR 
with longer incubation periods for all three antigens tested.  The presumed reason for a 
gradual increase in IR as incubation length increased in this study is that polyclonal 
antisera were used.  Each polyclonal antiserum has a heterogeneous mixture of 
antibodies, some of which may bind more slowly than others.  Only the antibodies with 
highest avidity for antigen will bind after short incubation periods.  It should be expected 
that longer incubation lengths in polyclonal antisera will allow for lower avidity 
antibodies (which are no less specific) to bind antigen (Polak and Van Noorden 2003).     
In this study, we showed that the sensitivity of immunofluorescence techniques can 
be affected by fixative composition and incubation length in primary antibody.  We used 
quantitative image analysis to objectively measure IR for GLS, Nav1.8, and TRPV1.  
Decreasing the formaldehyde concentration in the fixative from the commonly used 
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concentration of 4% led to an increase in IR for GLS and TRPV1, whereas adding picric 
acid, to the fixative led to an increase in IR for Nav1.8.  Determining the distribution of 
antigens in the DRG is of much importance for studying populations or subpopulations of 
DRG neurons.  Antigen distribution is often determined by the intensity of staining, 
therefore, increasing the sensitivity of immunofluorescence techniques may allow for 
other markers of DRG neuron subpopulations to be more accurately characterized. 
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Figure 2.1. Representative images from the formaldehyde comparison for GLS, Nav1.8, 
and TRPV1.  As formaldehyde concentration decreases, GLS-IR increased (A-E) in both 
small and large diameter DRG neurons.  Decreasing formaldehyde concentration did not 
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appear to have the same magnitude of effect on Nav1.8- (F-J) or TRPV1-IR (K-O).  At 
the highest concentration of formaldehyde (A), only small DRG neurons appear labeled 
for GLS, whereas with lower formaldehyde concentrations (C-E), all DRG neurons have 
GLS-IR.  Large neurons do not appear labeled for Nav1.8 or TRPV1, even at the lowest 




Figure 2.2. Scatter plots from the formaldehyde, picric acid, and primary incubation 
comparisons for GLS.  (A) Decreasing formaldehyde concentration in the fixative 
increased the relative immunoreactivity for both small and large DRG neurons such that 
each decrease in formaldehyde concentration resulted in an increase in relative 
immunoreactivity over the previous level.  (B) Changing the concentration of picric acid 
in the fixative did not have any effect on the relative immunoreactivity.  (C) Increasing 
incubation time in primary antiserum increased relative immunoreactivity for both small 
and large DRG neurons such that each increase in incubation resulted in higher relative 




Figure 2.3.  Effect of formaldehyde concentration in fixative on relative 
immunoreactivity means for small and large cells.  (A) Decreasing formaldehyde from 
4% had a concentration dependent effect, such that each decrease in concentration of 
formaldehyde resulted in GLS-IR being significantly (P<0.05 or better) higher than the 
previous concentration.  The effect was similar for both small and large DRG neurons.  
(B) Decreasing formaldehyde from 4% slightly increased Nav1.8-IR in small DRG 
neurons, however, there was no significant difference between 2%-0.25%, indicating a 
plateau of the effect.  Nav1.8-IR of large DRG neurons was only significantly elevated 
when 0.25% formaldehyde was used.  (C) Decreasing formaldehyde from 4% began to 
significantly increase TRPV1-IR of small DRG neurons at 1% and continued to increase 
it at 0.25%.  TRPV1-IR of large DRG neurons did not begin to significantly increase 
until 0.5% was used. (significance is indicated for comparisons against 4.00% 
formaldehyhde; *P<0.05, ***P<0.001) 
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Figure 2.4.  Correlations of formaldehyde concentration with IR for GLS, Nav1.8, and 
TRPV1.  (A) Formaldehyde concentration had a strong negative correlation with GLS-IR 
for both small and large cells, however, small cells maintained higher GLS-IR at all 
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formaldehyde concentrations.  (B) Nav1.8-IR did not have as strong of a negative 
correlation with formaldehyde concentration, albeit it was significant for both small and 
large cells.  The magnitude of the effect (slope) was not a large as for GLS-IR, but the 
small cells again maintained higher Nav1.8-IR at all formaldehyde concentrations.  (C) 
The correlation between TRPV1-IR and formaldehyde was again negative for both small 
and large cells, but not as strong or of as great a magnitude as for GLS-IR. 
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Figure 2.5.  Representative images from the picric acid comparison for GLS, Nav1.8, and 
TRPV1.  No obvious qualitative change in GLS-IR was observed as picric acid 
concentration was increased (A-E).  A slight increase in Nav1.8-IR was noticed in small 
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DRG neurons as picric acid was added to the fixative in increasing amounts, but there 
was not a noticeable change in the IR of large DRG neurons or background staining (F-J).  





Figure 2.6.  Effect of picric acid concentration in fixative on relative immunoreactivity 
means for small and large cells.  (A) Increasing picric acid in the fixative had no 
significant effect on GLS-IR for either small or large DRG neurons.  (B) In contrast, 
increasing the picric acid to 0.2% and higher significantly raised the Nav1.8-IR in small 
cells, but there was not a trend of significant elevation in IR for large DRG neurons as 
picric acid concentration was increased.  (C) TRPV1-IR of small DRG neurons increased 
as picric acid was added, but the effect reached a plateau at 0.2%.  Large DRG neurons 
only had significantly elevated IR at the highest concentration of picric acid. 





Figure 2.7.  Correlations of picric acid concentration with IR for GLS, Nav1.8, and 
TRPV1.  (A) There was no significant correlation between the concentration of picric 
acid in the fixative and GLS-IR for either small or large DRG neurons.  Small DRG 
neurons again had higher GLS-IR than large DRG neurons that was significant across all 
concentrations of picric acid (y-intercepts were significantly different). (B) There was a 
moderate but significant positive correlation between picric acid concentration and 
Nav1.8-IR for small DRG neurons.  The IR of large neurons did not correlate with picric 
acid concentration in the fixative.  (C) TRPV1-IR of both small and large DRG neurons 
had a weak but significant positive correlation with picric acid concentration.  The 
magnitude of the effect on small and large neurons was not significantly different (from 
comparing slopes), and the small neurons always had higher IR than large neurons over 
the entire range of picric acid concentrations tested (from comparing y-intercepts). 
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Figure 2.8.  Representative images from the primary antisera incubation comparison for 
GLS, Nav1.8, and TRPV1.  Extending the length of incubation in primary antiserum 
always increased the IR for the antigen studied.  Background levels of fluorescence also 
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increased at 96, 48, and 120 hours respectively for tissue processed for GLS (D), Nav1.8 
(H), and TRPV1 (O).  Maximal specific (e.g. neuronal) labeling appeared to occur at 96 




Figure 2.9.  Effect of incubation length in primary antiserum on relative 
immunoreactivity means for small and large cells.  (A) Maximal GLS-IR was obtained 
after 96 hours of incubation for both small and large DRG neurons.  (B) Nav1.8-IR of 
small DRG neurons reached maximal levels after 192 hours of incubation, while large 
DRG neurons reached maximal IR at 48 hours.  (C)  Incubating for 96 hours resulted in 
maximal TRPV1-IR of small and large DRG neurons. (significance is indicated for 




Figure 2.10.  Correlations of primary antiserum incubation length with IR for GLS, 
Nav1.8, and TRPV1.  Incubation length had a significant positive correlation with IR for 
all three antigens in small and large DRG neurons.  The correlation was strongest for 





Figure 2.11.  Optimization increases sensitivity of immunofluorescence detection for 
GLS, Nav1.8, and TRPV1.  Formaldehyde had a greater effect on GLS-IR in rat DRG 
neurons than picric acid.  When 4% formaldehyde is used 38% of rat DRG neurons are 
labeled for GLS (A) and they are primarily small neurons.  When formaldehyde is 
lowered to 0.25%, all rat DRG neurons are labeled (B).  Adding 0.8% picric acid to the 
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fixative increased the total number of DRG neurons labeled for Nav1.8 from 53% (C) to 
69% (D), with mainly small neurons contributing to the increased labeling.  TRPV1 was 
affected by both formaldehyde and picric acid concentrations, but only the effect of 
optimizing formaldehyde is shown here.  Lowering the formaldehyde concentration from 




Figure 2.12.  Control experiments for primary and secondary antisera.  The optimal 
fixation conditions of low formaldehyde (0.25%) and high picric acid (0.8%) were used 
to fix the DRG.  Diluted primary antisera were absorbed with antigen prior to routine 
processing (top three rows of panels).  Sections were incubated in primary antiserum 
diluent only and then routinely processed with one of the two secondary antisera (bottom 
row of panels).  IR for all three antigens was successfully absorbed out (right column, top 




Glutaminase immunoreactivity is increased during inflammation  
Abstract 
Glutamate is implicated as a neurotransmitter for both the peripheral and central 
terminals of nociceptive primary sensory neurons, yet little is known concerning 
regulation of glutamate metabolism during situations where these neurons are sensitized, 
such as peripheral inflammation.  Glutamate content of both the peripheral and central 
axons of pseudounipolar primary sensory neurons is elevated during inflammation.  
Glutaminase (GLS) is a constituent enzyme of the glutamate-glutamine cycle that 
converts glutamine into glutamate used for neurotransmission and is implicated, 
therefore, in producing these elevated levels of glutamate.  A potential mechanism for 
increased glutamate is an elevation in GLS expression.  To assess GLS expression during 
peripheral inflammation, we used the complete Freund’s adjuvant model for producing 
peripheral inflammation in the rat hind paw and measured GLS immunoreactivity (IR) in 
L4 dorsal root ganglion (DRG) neurons after one, two, four, and eight days of 
inflammation.  There was no significant elevation in GLS-IR in the DRG ipsilateral to the 
inflamed hind paw after one or two days of inflammation.  After four days of 
inflammation GLS-IR was elevated significantly in all DRG neurons.  After eight days of 
inflammation, GLS-IR only remained elevated in small (<600µm2), presumably 
nociceptive neurons.  The present study indicates that GLS expression is increased in the 
chronic stage of inflammation and may be a target for chronic pain therapy. 
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Introduction 
Central axons of pseudounipolar primary sensory neurons of the dorsal root ganglion 
(DRG) terminate in spinal cord dorsal horn and medullary dorsal column nuclei for pain 
and touch pathways, respectively (Martin 2003).  Peripheral axons of these neurons 
terminate in and bring sensory information from target tissues, such as viscera, muscle 
and skin.  The central axon terminals release the neurotransmitter glutamate at both spinal 
(Skilling, Smullin et al. 1988; De Biasi and Rustioni 1990; Zahn, Sluka et al. 2002; 
Dmitrieva, Rodriguez-Malaver et al. 2004) and medullary levels (De Biasi and Rustioni 
1990).  Although the peripheral axon terminals are afferent receptors, some of them also 
have efferent capabilities (Sann and Pierau 1998), e.g., glutamate release in response to 
noxious stimulation (Omote, Kawamata et al. 1998; deGroot, Zhou et al. 2000; Jin, 
Nishioka et al. 2006).  Inflammation of peripheral target tissues increases the amount of 
glutamate released from both the peripheral (Omote, Kawamata et al. 1998; Jin, Nishioka 
et al. 2006) and central axon terminals of DRG neurons (Skilling, Smullin et al. 1988; 
Dmitrieva, Rodriguez-Malaver et al. 2004).  Similar phenomena occur with the 
neuropeptides substance P and calcitonin gene-related peptide (CGRP).  In these 
instances, inflammation induces gene regulation at the transcriptional level, providing the 
elevated amounts of substance P and CGRP for release from peripheral and central 
terminals (Woolf and Salter 2000; Woolf and Ma 2007).  In contrast, increasing the 
amount of the amino acid glutamate available for release depends on regulation at the 
level of the enzyme that synthesizes glutamate, glutaminase (GLS).  Despite being 
released from the same neurons that release neuropeptides (Merighi, Polak et al. 1991) 
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and colocalization of GLS within peptidergic neurons (Miller, Douglas et al. 1993), very 
little is known about glutamate metabolism in DRG neurons during inflammation. 
 Glutamate metabolism in the central nervous system (CNS) has been well studied 
(McKenna 2007), since glutamate is the primary excitatory neurotransmitter in the CNS.  
Neurotransmitter glutamate is taken up and converted to glutamine by astrocytes via the 
enzyme glutamine synthetase, which release glutamine back to the neurons.  Neurons 
take up glutamine and convert it to glutamate with GT.  Many of the proteins necessary 
for the glutamate-glutamine cycle are present in DRG neurons and their glia (Berger and 
Hediger 2000; Miller, Richards et al. 2002; Tao, Liaw et al. 2004; Miller, Kriebel et al. 
2005).  Increasing the production of glutamate available for release in DRG neurons 
would involve an increase in flux through the glutamate-glutamine cycle near the sites of 
glutamate release.  Long-term responses may require regulating the expression of 
glutamate-glutamine cycle proteins at the cell body in the DRG and then transporting 
them to the peripheral and central terminals.  To address this issue, we hypothesized that 
hind paw inflammation increases GLS production in rat DRG neurons.  In the present 
study, we examined GLS levels using immunofluorescence in rat DRG neurons after one, 
two, four, and eight days of hind paw inflammation.  The preliminary results for this 
study have been presented in poster form (Hoffman, Edwards et al. 2007).   
Methods 
A combination of male and female Sprague-Dawley rats (n=32; 170-280g) bred on 
site were used for this study.  They were housed on a 12 hour light: 12 hour dark cycle 
and given free access to food and water.  Procedures in this study were conducted 
according to guidelines from the International Association for the Study of Pain 
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(Zimmermann 1983) and the National Institutes of Health (NIH 2003), and were 
approved by the Oklahoma State University – Center for Health Sciences Institutional 
Animal Care and Use Committee.  All appropriate efforts were made to minimize the 
number of rats used in this study. 
To induce a unilateral inflammation of the hind paw, rats (n=20) were immobilized 
while 150 µL of a 1:1 emulsion containing complete Freund’s adjuvant (CFA; Sigma; St. 
Louis, MO, USA) and 10 mM phosphate buffered 0.9% saline (PBS) was injected into 
the plantar surface of the right hind paw using a 26 gauge needle.  Control rats (n=12) 
were given an injection of 150 µL PBS in the right hind paw with the same immobilizing 
procedure, needle, and injection technique.  Inflammation was allowed to persist for one, 
two, four, or eight days; at each time point, 5 CFA-injected and 3 PBS-injected animals 
were used for immunofluorescence experiments. 
 Behavioral studies were performed to verify the presence of hyperalgesia after 
induction of inflammation.  Rats were housed in a behavioral testing room within the 
animal facility to familiarize them to the testing environment and to minimize the 
experience of transfer to and from testing chambers and housing cages.  At least two 
handling sessions, each on a different day, occurred before starting any behavioral tests.  
A handling session consisted of placing rats in both types of testing chamber for one hour 
each and manually moving them between cages and testing chambers.  This familiarized 
the rats to being placed into the temporary environments by the experimenters. 
 Three days of testing were performed prior to the injection day to obtain a baseline 
reading for each animal; these days were noted as days -3, -2, and -1.  On injection day 
(day 0), the behavioral test was done prior to the injection, thus serving as a fourth and 
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final assessment of baseline sensitivity.  Behavioral testing continued daily at the same 
approximate time each day throughout the remainder of each individual experiment, with 
the longest being until day 8 (12 total days of testing). 
 Thermal latencies measured in seconds were obtained using a Plantar Test apparatus 
(Ugo Basile, Comerio, Italy) set at an intensity of 55 mW/cm2
 After one, two, four, or eight days of inflammation, 3 PBS-injected and 5 CFA-
injected rats were anesthetized with intraperitoneal (i.p.) injections of 1.5 mL 2.5% (w/v) 
Avertin followed by 0.5 mL xylazine.  Rats were perfused with 75 mL of calcium-free 
Tyrode’s solution, pH 7.3 followed by 325 mL of 0.96% (w/v) picric acid and 0.2% (w/v) 
formaldehyde in 0.1M sodium phosphate buffer, pH 7.3.  We chose this fixative because 
low aldehyde concentration results in optimal immunolabeling of GLS (Kaneko, Itoh et 
al. 1989; Hoffman, Edwards et al. 2008).  The left and right L4 DRG were carefully 
dissected and placed in the same fixative for 24 hours at 4°C before being transferred to 
.  Mechanical thresholds 
measured in grams were obtained using a Dynamic Plantar Aesthesiometer (Ugo Basile) 
set to apply a maximum of 50 g at a ramp rate of 5 g/s.  Each testing period consisted of 
placing the rats into the testing chambers where acclimation was indicated by cessation of 
all exploratory and grooming behaviors.  Two thermal latencies and two mechanical 
thresholds were measured from each hind paw of each rat, with measurements spaced at 
least ten minutes apart. 
 Hind paw edema was measured with a dial caliper (Mitutoyo; Aurora, IL, USA) by 
measuring metatarsal thickness to the nearest 0.05 mm of both hind paws on the day that 
the rat was perfused.  All hind paw edema measurements were taken when animals were 
47-48 days old so that age would not confound the results. 
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20% (w/v) sucrose in 0.1M sodium phosphate buffer, pH 7.3 for 48 hours at 4°C.  The 
sixteen DRG from a given set of animals were embedded in a single frozen block and cut 
in 10 µm sections on a Microm HM 550 OMVP cryostat (Richard Allan Scientific; 
Kalamazoo, MI, USA).  Every fourth section was thaw mounted on gelatin-coated 
SuperFrost slides (Fischer Scientific; Pittsburg, PA, USA) with two sections per slide.  
Five slides of DRG sections from each time point were dried at 37°C for two hours.  
After three 10 minute rinses in PBS, DRG sections were blocked for one hour at room 
temperature in 10% (v/v) normal goat serum, 10% (v/v) fetal bovine serum, 10% (v/v) 
normal horse serum, 2% (w/v) polyvinylpyrollidone, 2% (w/v) bovine serum albumin, 
and 0.3% (v/v) Triton X-100 in PBS.  A polyclonal rabbit antiserum against glutaminase 
was a generous gift from Norman Curthoys (Colorado State University, Ft. Collins, CO, 
USA).  The primary antiserum was diluted 1:10,000 in PBS containing 0.3% (w/v) Triton 
X-100 (PBS-T) and DRG sections were incubated for four days at 4°C.  After primary 
antiserum incubation, DRG sections were rinsed three times for 10 minutes in PBS and 
incubated for one hour at room temperature in biotinylated goat anti-rabbit (Vector 
Laboratories; Burlingame, CA, USA) diluted in PBS-T to 1.5 µg/mL.  DRG sections 
were rinsed two times in PBS for 10 minutes and one time in 0.1M sodium carbonate 
buffered 0.9% (w/v) saline (SCBS) for 10 minutes before one hour of incubation at room 
temperature in fluorescein isothiocyanate conjugated avidin (Vector Laboratories) diluted 
to 1 µg/mL in SCBS.  After three 10 minute rinses in PBS, cover slips were affixed with 
ProLong Gold (Invitrogen; Carlsbad, CA, USA) to retard fading of immunofluorescence. 
 Images were acquired on a BX51 epifluorescence microscope (Olympus; Center 
Valley, PA, USA) using a SPOT RT740 camera (Diagnostic Instruments; Sterling 
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Heights, MI, USA).  An exposure and gain combination was determined empirically for 
each of the four slide sets in which the dimmest regions of tissue could be discerned 
visually for tracing, but the brightest regions were not oversaturated.  Three fields of view 
were captured randomly from each section of each DRG.  All nucleated cells were 
analyzed in ImageJ (National Institutes of Health; Bethesda, MD, USA) by using the 
freehand selection tool to identify the cells as regions of interest (ROIs).  Once all ROIs 
for a given image were selected and added to the ROI manager, the area (in µm2) and 
mean gray values were measured for each cell and exported for subsequent statistical 
analysis.  Each pixel of an 8-bit grayscale image can have a value from 0-255.  We 
converted each mean gray value (C) into a relative mean gray value that ranged from 1-
100 (Fang, Djouhri et al. 2006), because images from each of the four slide sets were 
taken at slightly different gain and exposure settings.  To do this, we found the mean gray 
value of the most weakly labeled neuron in each data set (A) and the mean gray value of 
the most intensely labeled neuron in each data set (B); each neuron was given a relative 
mean gray value = (100 × (C-A)/(B-A)). Mean gray values quantitate the 
immunoreactivity (IR) and therefore estimate protein expression.  The relative mean gray 
value and size (in µm2) for each cell were shown in x-y scatterplots.  Frequency 
distributions of relative mean gray values were also generated for each time point.  At 
each of the four time points assessed, the mean relative mean gray value were calculated 
for small (<600 µm2) and large (>600 µm2
 Graphs and statistical calculations were performed in GraphPad Prism version 5.01 
for Windows (GraphPad Software; San Diego, CA, USA).  Two-way ANOVAs were 
done to determine if effects of inflammation or time were significant on thermal latency, 
) neurons of each L4 DRG. 
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mechanical threshold, and hind paw edema data.  Bonferroni post-tests were performed to 
determine which groups differed and when.  A two way ANOVA was done on each of 
the four sets of GLS-IR data to determine if effects of inflammation were significant on 
the mean GLS-IR of small and large L4 DRG neurons.  Bonferroni post-tests were 
performed to determine which DRG and which neuron populations differed significantly 
in GLS-IR.  All graphical results represent mean plus or minus the standard deviation.  
Results were considered significant when p values were less than 0.05. 
Results 
 Thermal latencies and mechanical thresholds of the hind paws contralateral to the 
PBS injection, ipsilateral to the PBS injection or contralateral to the CFA injection were 
never significantly different from each other.  Baseline thermal latencies of the hind paws 
ipsilateral to the CFA injection were not significantly different than the other baseline 
measurements, but they were always significantly different from the three other groups 
after the injection at day 0 through day 4.  Thermal latencies of hind paws ipsilateral to 
the CFA injection were not different than those from hind paws ipsilateral to the PBS 
injection on days 5, 7 or 8 (Figure 3.1A).  Baseline mechanical thresholds of the hind 
paws ipsilateral to the CFA injection were not significantly different than the other 
baseline measurements, but they were always significantly different from the three other 
groups after the injection at day 0 through day 8 (Figure 3.1B). 
 Metatarsal thickness of the hind paws contralateral to PBS and CFA injections were 
not significantly different from the PBS injected paws at any of the four time points.  
Metatarsal thickness was increased significantly (p < 0.001) in the hind paws ipsilateral 
to CFA injection compared to the other three groups of hind paw at all four time points 
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with a peak increase at 2 days (Figure 3.1C).  The relative increases of the CFA-injected 
paw versus the PBS-injected paw were 67%, 84%, 52%, and 28%, for days 1, 2, 4, and 8, 
respectively. 
 Representative images from the DRG ipsilateral to the CFA injection after one, two, 
four, and eight days of inflammation showed a qualitative difference in the GLS-IR, 
especially after four days of inflammation (Figure 3.2, left bottom panel).  The area (in 
µm2) and GLS-IR (relative mean gray value) for each neuron profile were plotted on the 
x and y axes, respectively for each time point in the study (Figure 3.3).  There did not 
appear to be any obvious differences in GLS-IR after one or two days of inflammation 
(Figure 3.3A and 3.3B).  However, a robust elevation in GLS was evident after four days 
of inflammation (Figure 3.3C) that appeared to persist in some small neurons even after 
eight days of inflammation (Figure 3.3D).  For a better appreciation of the GLS-IR 
changes, frequency distributions were made for GLS-IR (Figure 3.4).  The frequency 
distributions of GLS-IR intensity appear similar between different groups of DRG after 
one and two days of inflammation (Figures 3.4A and 3.4B); whereas there is an 
observable “right shift” in the distribution of GLS-IR intensity in DRG ipsilateral to the 
CFA injection after four days of inflammation (Figure 3.4C).  The GLS-IR frequency 
distribution in the DRG ipsilateral to CFA injection after eight days of inflammation is 
slightly right shifted from the frequency distributions of other DRG at this time point 
(Figure 3.4D).  The means of the relative mean gray values for DRG contralateral to the 
CFA injection showed a significant increase after one day of inflammation (Figure 3.5A), 
but there were no significant differences after two days of inflammation (Figure 3.5B).  
After four days of inflammation, the GLS-IR in the DRG ipsilateral to the CFA injections 
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was significantly increased over all three other groups of DRG in both small and large 
DRG neurons (Figure 3.5C).  The approximate magnitude of GLS-IR elevation in small 
and large neurons after four days of inflammation was similar.  There was a smaller albeit 
significant elevation of GLS-IR in small and large neurons of the DRGs ipsilateral to the 
PBS injection and contralateral to the CFA injection.  By eight days post injection, there 
was still a significant elevation of GLS-IR in the small neuron ipsilateral to the CFA 
injection, but there were no differences in the other groups of DRG (Figure 3.5D).  GLS-
IR in large neurons ipsilateral to the CFA injection was not significantly different from 
the three other groups of DRG after eight days of inflammation.  
Discussion 
 Peripheral sensitization of DRG neurons during inflammation initiates a sensitizing 
cascade along the pain pathway resulting in the chronic pain state.  Both post-
translational and expression dependent mechanisms are involved in peripheral 
sensitization; the former for initiation of sensitization during the acute stage of 
inflammatory pain and the latter for maintaining the sensitization during the chronic stage 
(Woolf and Ma 2007).  Many proteins involved in peripheral sensitization undergo both 
types of changes.  For instance, transient receptor potential vanilloid subfamily member 1 
(TRPV1) is released from phosphatidylinositol-4,5-bisphosphate inhibition (Chuang, 
Prescott et al. 2001) and is phosphorylated by protein kinase C (Sugiura, Tominaga et al. 
2002) in the acute stage of inflammatory pain, and its synthesis increases in the chronic 
stage (Ji, Samad et al. 2002; Xue, Jong et al. 2007).  Both mechanisms contribute to 
sensitization of the DRG neuron (Chuang, Prescott et al. 2001; Sugiura, Tominaga et al. 
2002) and behavioral hyperalgesia (Ji, Samad et al. 2002; Ferreira, da Silva et al. 2004).  
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While GLS does not have a phosphorylation site, its activity can be modulated by 
allosteric factors such as calcium and inorganic phosphate (Kvamme, Torgner et al. 
2001), whose concentrations would increase in an activated peripheral or central axon 
terminal.  For example, increased synaptic activity increases hydrolysis of ATP into ADP 
and inorganic phosphate and it increases calcium influx through voltage-gated calcium 
channels (Altier and Zamponi 2004) and members of the TRP family (Bautista, Jordt et 
al. 2006).  Therefore, increased synaptic activity during the acute stage of inflammation 
could increase GLS activity and account for the elevated amounts of glutamate seen in 
the skin (Omote, Kawamata et al. 1998; Jin, Nishioka et al. 2006), peripheral axons 
(Westlund, Sun et al. 1992), and spinal cord dorsal horn within hours after the induction 
of inflammation (Skilling, Smullin et al. 1988; Dmitrieva, Rodriguez-Malaver et al. 
2004).  In the current study, however, DRG neurons also appear to increase expression of 
GLS and possibly transport it out of the cell body in the chronic stage of inflammation.  
Based on the timescale of increased GLS production, it is possible that a retrogradely 
transported neurotrophic factor such as nerve growth factor (NGF) is responsible for this 
regulation.  The timescale of GLS up-regulation is similar to the up-regulation of 
substance P and CGRP after five days of inflammation, which was preventable with anti-
NGF treatment (Donnerer, Schuligoi et al. 1992).  Retrograde NGF signaling also could 
account for subsequent anterograde transport out of newly synthesized GLS out of the 
cell body via mitochondrial axonal transport (Chada and Hollenbeck 2003; Chada and 
Hollenbeck 2004).  This type of regulation parallels the post-translational modification 
followed by expressional regulation dogma mentioned earlier (Woolf and Ma 2007).  
Moreover, NGF regulates expression of several other proteins important for nociception 
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(Pezet and McMahon 2006), and has the ability to affect GLS expression in DRG 
neurons (McDougal, Yu et al. 1981; Miller, Akesson et al. 1999; Miller, Caire et al. 
2001) and retina (Tomita, Ishiguro et al. 1999).   
 Glutamate is implicated not only as a neurotransmitter released by nociceptive 
peripheral axon terminals but also as a sensitizer of these terminals.  Injecting glutamate 
or glutamate receptor agonists sensitize nociceptors in ex vivo (Du, Koltzenburg et al. 
2001) studies and causes hyperalgesia in vivo in rodents (Carlton, Hargett et al. 1995; 
Jackson, Graff et al. 1995; Carlton, Zhou et al. 1996; Zhou, Bonasera et al. 1996; 
Davidson, Coggeshall et al. 1997; Lawand, Willis et al. 1997; Carlton, Zhou et al. 1998; 
Carlton and Coggeshall 1999; Giovengo, Kitto et al. 1999; Bhave, Karim et al. 2001) and 
humans (Gazerani, Wang et al. 2006).  The role of glutamate in mediating hyperalgesia 
during inflammation is evidenced by high glutamate levels in inflamed tissues (Nordlind, 
Johansson et al. 1993; Lawand, McNearney et al. 2000) and the attenuation of 
hyperalgesia with glutamate receptor antagonists in inflammatory animal models 
(Jackson, Graff et al. 1995; Lawand, Willis et al. 1997; Bhave, Karim et al. 2001; Du, 
Zhou et al. 2003) and burn injury in humans (Warncke, Jorum et al. 1997).  Glutamate 
may exacerbate the neurogenic component of inflammation by further activation of SP 
and SP and CGRP release (Yu, Sessle et al. 1996).  The numbers of glutamate receptors 
on peripheral axons also increases during inflammation (Carlton and Coggeshall 1999; 
Du, Zhou et al. 2003), which could lead to an escalating cycle wherein the peripheral 
terminals are able to maintain their own sensitization and exacerbate chronic pain 
(Carlton 2001).  Similarly, glutamate is involved in sensitization of dorsal horn neurons 
to afferent stimulation (Dougherty and Willis 1991; Dougherty, Palecek et al. 1993; Hu, 
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Alter et al. 2007; Pezet, Marchand et al. 2008).  The presence of glutamate receptors on 
central axon terminals (Liu, Wang et al. 1994) could enhance central glutamate release 
via a positive feedback mechanism.  Therefore, increased glutamate production may be 
involved in both peripheral and central sensitization mechanisms that culminate in 
chronic pain.  
 Since GLS is only one of many proteins involved in the glutamate-glutamine cycle, 
other proteins within the cycle may need to increase their activities and/or expressions in 
order to effectively increase the flux of glutamate through the cycle.  Although many of 
these proteins have at least been localized to the DRG and peripheral nerve, very little is 
known about the glutamate-glutamine cycle during inflammation.  The neuronal 
glutamate transporter responsible for reuptake of glutamate, excitatory amino acid 
transporter 3 (EAAT3), localizes to primarily small diameter DRG neurons (Tao, Liaw et 
al. 2004) and the glial glutamate transporter, EAAT1, localizes to satellite glial cells of 
the DRG (Berger and Hediger 2000).  Glutamine synthetase, the glial enzyme that 
converts glutamate to glutamine, not only serves as a specific marker for satellite glial 
cells in the rat DRG (Miller, Richards et al. 2002) and mouse trigeminal ganglia (TG) 
(Weick, Cherkas et al. 2003; Hanani 2005), but increases along with glutamine in satellite 
glial cells after inflammation (Miller and Kriebel 2003).  Increases in GS and glutamine 
concur with the notion that multiple glutamate-glutamine cycle proteins and substrates 
increase in response to inflammation.  Little is known concerning glutamine transporters 
in the DRG, but we have detected sodium-coupled neutral amino acid transporters 
(SNAT) 1 (Miller, Kriebel et al. 2005) and 2 (unpublished results) in DRG neurons.  
Vesicular glutamate transporters (VGLUTs) are necessary at sites of glutamate 
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neurotransmission and VGLUT1 and 2 localize to different size classes of DRG (Morris, 
Konig et al. 2005; Brumovsky, Watanabe et al. 2007) and TG (Li, Xiong et al. 2003) 
neuron cell bodies in addition to the peripheral (Nunzi, Pisarek et al. 2004; Brumovsky, 
Watanabe et al. 2007) and central (Li, Fujiyama et al. 2003; Morris, Konig et al. 2005) 
terminals.  Regulation of VGLUT1 and 2 levels at the cell body occurs after peripheral 
axotomy (Brumovsky, Watanabe et al. 2007) and VGLUT2 expression appears to 
regulate glutamate release during neuropathic pain (Moechars, Weston et al. 2006).  
However, information about alterations of VGLUT during inflammation is lacking.  We 
hypothesize that post-translational and/or expression dependent mechanisms may act on 
some or all of the aforementioned proteins to increase glutamate production during 
inflammation and contribute to peripheral and central sensitization.  Support for this 
hypothesis comes from the observations that pharmacological intervention of GLS with 
an irreversible inhibitor at the peripheral terminal (Miller, Herzog et al. 2006) or 
glutamine transporter (Chiang, Li et al. 2008) and GS (Chiang, Wang et al. 2007) 
inhibition at the central terminals and second order neurons in dorsal horn provide 
analgesia during inflammation. 
 The present results indicate that an increase in GLS production occurs during the 
chronic stage of inflammatory pain.  Further study of glutamate-glutamine cycle proteins 
both peripherally and centrally during inflammation is necessary to fully understand the 
role glutamate metabolism plays in peripheral and central sensitization.  It is expected 






Figure 3.1.  Thermal latencies , mechanical thresholds , and metatarsal thicknesses from 
rat hind paws after injection with PBS or CFA on day 0.  Injection of CFA caused 
significant decreases in thermal latencies (A) for days 1 through 4 and mechanical 
thresholds (B) for days 1 through 8.  Thermal latencies appeared to be decreased for days 
5 through 8, but significance could not be shown with sample sizes of n = 3 for PBS and 
n = 5 for CFA.  Behavioral data from all four sets were combined; therefore, the number 
of rats contributing data declines as the study progressed.  Edema measurements (C) for 
each time point consist of 3 PBS-injected rats and 5 CFA-injected rats.  There was always 
a significant increase in edema in the CFA-injected hind paw, with peak swelling 
occurring after two days of inflammation.  Data are graphed as means (±SD).  *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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Figure 3.2. Representative images of GLS immunofluorescence of L4 DRG neurons 
ipsilateral to the CFA-injected hind paw after one, two, four, and eight days of 
inflammation.  Very few neurons had high GLS-IR after one and two days of 
inflammation (arrows).  However, after four days of hind paw inflammation GLS-IR in 
many neurons increased (arrows).  After eight days of inflammation GLS-IR was still 





Figure 3.3. Scatter plots of the GLS-IR as relative mean gray values (y-axis) and the cell 
size in square microns (x-axis).  Each point represents a single neuron profile after one 
(A), two (B), four (C), or eight (D) days of inflammation.  The different types of DRG 
are indicated by color.  Plots for different types of DRG look similar after one and two 
days of inflammation.  Elevation of GLS-IR intensities is apparent after four days of 
inflammation in cells of all sizes from the DRG ipsilateral to CFA injection.  After eight 
days of inflammation, some small DRG neurons still have elevated GLS-IR. 
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Figure 3.4.  Frequency distributions for GLS-IR in L4 DRG neurons after hind paw 
inflammation.  There was a subtle shift to the right in the frequency distribution for DRG 
neurons contralateral to the CFA injection after one day of inflammation.  After four days 
of inflammation, there was a right shift of the GLS-IR frequency distributions for the 
DRG neurons ipsilateral to the PBS injection and contralateral to the CFA injection as 
compared to the DRG neurons contralateral to the PBS injection.  In addition, there was a 
larger shift to the right in the frequency distribution for the neurons ipsilateral to the CFA 
injection at the four day time point.  After eight days of inflammation, there was only a 




Figure 3.5.  Mean GLS-IR in small and large L4 DRG neurons after hind paw 
inflammation.  The means of the relative mean gray values for DRG contralateral to the 
CFA injection showed a significant increase after one day of inflammation (A), but there 
were no significant differences after two days of inflammation (B).  After four days of 
inflammation, the GLS-IR in the DRG ipsilateral to the CFA injections was significantly 
increased over all three other groups of DRG in both small and large DRG neurons 
(Figure 5C).  By eight days post injection, there was still a significant elevation of GLS-









Nerve growth factor (NGF) levels are elevated during inflammation, which increases 
sensitivity of nociceptive nerve fibers innervating inflamed tissue.  Antagonism of NGF 
is gaining support as a novel therapy for inflammatory and neuropathic pain.  The most 
effective NGF antagonists to date are anti-NGF antibodies, which are presumed to 
sequester endogenous NGF and prevent its interaction with NGF receptors.  
Autoimmunization with NGF is a useful experimental model for studying the effects of 
chronic, steady levels of anti-NGF antibodies.  High serum anti-NGF levels were 
previously correlated with hypoalgesia after NGF autoimmunization, but the mechanism 
was not determined.  In the present study, we studied this mechanism by immunizing rats 
against NGF and evaluating their sensory sensitivity, serum anti-NGF levels, degree of 
NGF deprivation as indicated by sympathetic ganglion atrophy, and two markers of 
dorsal root ganglion (DRG) neuron function: glutaminase (GLS) and voltage-gated 
sodium channel 1.8 (Nav1.8).  All DRG neurons express the enzyme GLS for making the 
neurotransmitter glutamate, while only nociceptive DRG neurons express Nav1.8.  
Impairment of GLS expression could, therefore, reduce fidelity of DRG neuron 
communication with the central nervous system for all sensory modalities, while
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decreased Nav1.8 expression would only affect nociception.  We found that NGF 
deprivation decreased sensitivity to pain and decreased basal Nav1.8 expression in a 
subpopulation of nociceptive DRG neurons, but it did not affect basal GLS expression in 
these neurons or other sensory modalities.  We conclude that the mechanism of 
hypoalgesia during NGF deprivation does not involve decreased GLS expression, but 
may involve decreased Nav1.8 expression. 
Introduction 
 Nerve growth factor (NGF) is produced by peripheral tissues and influences the 
function of afferent and autonomic nerve fibers innervating these tissues.  Inflammation 
increases production of NGF (Woolf, Safieh-Garabedian et al. 1994; Sivilia, Paradisi et 
al. 2008), which in turn sensitizes nociceptive afferents through post-translational and 
expression dependent mechanisms (Pezet and McMahon 2006).  Therefore, antagonizing 
NGF has become a research focus for treatment of inflammatory pain (Hefti, Rosenthal et 
al. 2006; Watson, Allen et al. 2008).  Although small molecule NGF receptor antagonists 
have been developed (Owolabi, Rizkalla et al. 1999; Colquhoun, Lawrance et al. 2004), 
antibodies against NGF remain the most effective means of blocking NGF-induced 
changes in nociceptors (Koltzenburg, Bennett et al. 1999; Covaceuszach, Cattaneo et al. 
2005; Sevcik, Ghilardi et al. 2005; Hefti, Rosenthal et al. 2006; Abdiche, Malashock et 
al. 2008).  Administering anti-NGF antibodies systemically (Ma and Woolf 1997) or 
locally (Bennett, Koltzenburg et al. 1998; Gould, Gould et al. 2000; Djouhri, Dawbarn et 
al. 2001) at the site of inflammation attenuates nociceptor sensitization and provides 
analgesia in animal inflammatory pain models (McMahon 1996).   
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 Autoimmunization against NGF is an effective experimental model for studying the 
effects of NGF deprivation on peripheral neurons.  Sympathetic neurons, which rely on 
continual NGF release from their peripheral targets, undergo severe atrophy after NGF 
autoimmunization (Otten, Goedert et al. 1979; Gorin and Johnson 1980; Johnson, Gorin 
et al. 1982).  Sensory neurons in the adult dorsal root ganglion (DRG) undergo slight 
atrophy and have decreased expression of specific proteins like SP and the voltage-gated 
sodium channel Nav
 All DRG neurons use the neurotransmitter glutamate for release from central 
terminals onto second order sensory neurons in the spinal cord dorsal horn (Merighi, 
Polak et al. 1991; Zahn, Sluka et al. 2002) and medullary dorsal column nuclei (De Biasi 
and Rustioni 1990; Giuffrida and Rustioni 1992).  Glutaminase (GLS) is the neuronal 
1.8 (Schwartz, Pearson et al. 1982; Fjell, Cummins et al. 1999).  
NGF autoimmunization leads to sympathectomy (Gorin and Johnson 1979; Otten, 
Goedert et al. 1979) and hypoalgesia (Chudler, Anderson et al. 1997), which are 
symptoms similar to those of humans affected by congenital insensitivity to pain with 
anhydrosis (CIPA) where the high affinity NGF receptor TrkA is mutated (Indo 2001).  
Sympathectomy is due to severe atrophy of autonomic neurons, whereas the mechanism 
underlying hypoalgesia is less clear.  Aside from being required for survival of sensory 
neurons during development, NGF plays a role in regulating normal sensitivity of 
nociceptors (McMahon, Bennett et al. 1995; McMahon 1996; Bennett, Koltzenburg et al. 
1998), which still express TrkA in adulthood (McMahon, Armanini et al. 1994; Phillips 
and Armanini 1996). This is thought to occur by regulating basal expression of proteins 
important for nociception, such as SP and calcitonin gene-related peptide (CGRP), which 
contribute to edema and vasodilation (Pezet and McMahon 2006). 
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enzyme that converts glutamine into glutamate and all DRG neurons express this enzyme 
(Miller, Douglas et al. 1993; Li, Ohishi et al. 1996).  In addition to SP and CGRP, 
nociceptors also have the ability to release glutamate at their peripheral terminals 
(Omote, Kawamata et al. 1998; deGroot, Zhou et al. 2000; Carlton 2001; Jin, Nishioka et 
al. 2006; Brumovsky, Watanabe et al. 2007).  If GLS expression is decreased in 
nociceptors, then both peripheral and central glutamatergic transmission may be affected, 
which could lead to decreased fidelity of nociceptive transmission. 
 Nav1.8 is exclusively expressed in nociceptive DRG neurons (Djouhri, Fang et al. 
2003), and Nav1.8 mRNA expression as well as current density are decreased after NGF 
deprivation via autoimmunization (Fjell, Cummins et al. 1999).  The aim of the current 
study was to determine if there is a change in GLS or Nav1.8 expression in nociceptive 
DRG neurons after NGF deprivation via autoimmunization.  Immunization effectiveness 
was evaluated by obtaining serum anti-NGF titers.  Deprivation of NGF was confirmed 
by observing superior cervical ganglion (SCG) morphology.   Previous anti-NGF studies 
(Chudler, Anderson et al. 1997) had only examined hot plate responses, so we used 
additional sensory tests to better determine the behavioral effects of NGF deprivation. 
Methods 
Sprague-Dawley rats (n = 31) were housed on a 12 hour light: 12 hour dark cycle and 
given free access to food and water.  Procedures were conducted according to guidelines 
from the International Association for the Study of Pain (Zimmermann 1983) and were 
approved by the Oklahoma State University Center for Health Sciences Institutional 
Animal Care and Use Committee.  All appropriate efforts were made to minimize the 
number of animals used in this study. 
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 To determine the effect of immunization on behavioral responses, the proportion of 
rats expected to have high anti-NGF titer, and the duration of antibody production, 12 rats 
were immunized against cytochrome C, and their behavioral responses and antibody titers 
were compared to naïve rats (n = 3).  To determine the effects of NGF deprivation, rats in 
a second experiment were randomly assigned to either the control/cytochrome C group 
(cytC; n=6) or experimental/NGF group (n=10).  At six weeks of age, rats in both 
experiments were immunized with the appropriate antigen: cytochrome C from horse 
heart (Sigma) or 2.5S NGF from mouse submandibular gland (Affinity BioReagents).  
Each rat was anesthetized with isoflurane prior to giving four dorsal paraspinal 
subcutaneous injections (~25 µL each) of antigen in complete Freund’s adjuvant (CFA; 
Sigma); the total initial immunization dose for each rat was 20 µg in 100 µL CFA.  At ten 
weeks of age, rats were given a booster immunization with the appropriate antigen using 
the same injection method used for the initial immunization; the total booster 
immunization dose for each rat was 50 µg in 100 µL CFA.   
 Antibody titer measurements were obtained from serum and cerebrospinal fluid 
(CSF) samples using an enzyme-linked immunosorbant assay (ELISA).  For serum 
collection, rats were anesthetized with isoflurane and laid on a heating pad to aid in 
vasodilatation.  A 26G needle attached to a syringe with the plunger removed was used to 
collect ~150 µL of blood from one of the lateral tail veins (Brown 2006).  Whole blood 
was incubated at 37°C for one hour to aid clotting and then stored overnight at 4°C.  The 
sample was centrifuged at 10,000 × g for 15 minutes at 4°C to dislodge the clot.  Serum 
(~50 µL) was collected from the top of the supernatant.  The following dilutions of serum 
were made in PBS-Tween (100 mM sodium phosphate, 150 mM sodium chloride, 0.05% 
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(v/v) Tween-20, pH 7.2): 1:2000, 1:4000, 1:8000, 1:16000, 1:32000, 1:48000, 1:64000, 
1:96000.  Multi-well plates were coated with 2 µg/mL of appropriate antigen (cytC or 
NGF) diluted in 50 mM sodium carbonate buffer, pH 9.6 overnight at 4°C.  Wells were 
rinsed three times for five minutes with PBS-Tween.  Wells were blocked with 5% (v/v) 
normal goat serum in PBS-Tween for one hour at room temperature.  Dilutions of sera 
were applied and incubated for one hour at 37°C.  Wells were rinsed three times for five 
minutes with PBS-Tween and incubated for one hour at 37° in horseradish peroxidase-
conjugated goat anti-rat (Sigma) diluted 1:1000 in PBS-Tween.  Wells were rinsed three 
more times with PBS-Tween before adding 100 µL 0.04% (w/v) o-phenylenediamine 
(OPD) in 50 mM phosphate-citrate buffer, pH 5.0 containing 0.012% (v/v) hydrogen 
peroxide.  The OPD reaction was stopped with 50 µL 2.5 N sulfuric acid.  The reaction 
product was measured by determining the absorption at 492 nm.  Titer was determined as 
the most dilute sera that gave an absorbance reading at least twice that of pre-immune 
serum samples from each rat taken at 5 weeks of age.  Sera of rats in the first experiment 
(n=15) were measured at 8, 11, 12, 13, and 14 weeks of age.  Sera of rats in the second 
experiment (n=16) were measured at 11, 12, and 14 weeks of age, and CSF was measured 
only at 14 weeks of age from high titer NGF and cytC rats.  Cerebrospinal fluid was 
sampled immediately prior to tissue collection by surgically revealing the dura mater over 
cisterna magna in anesthetized rats and piercing it with the collection needle to avoid 
contamination with blood.  Additional controls performed with each ELISA include: 
minus antigen control, minus primary control, and minus secondary control. 
 Behavioral studies were performed to determine if sensory thresholds were affected 
by immunization with cytC or NGF as previously reported (Otten, Ruegg et al. 1982; 
 91 
Chudler, Anderson et al. 1997).  Four different tests were used: thermal latency, 
mechanical threshold, hot plate, and tail flick.  Thermal latencies and mechanical 
thresholds were assessed at 5, 9, 11, 12, and 14 weeks of age by measuring each hind 
paw three times with at least 10 minutes between measurements.  Thermal latencies were 
measured with the Plantar Test apparatus (Ugo Basile) set at 55 mW/cm2
 At 14 weeks of age, rats in the second experiment (n=16) were anesthetized with 
Avertin and xylazine and transcardially perfused with 75 mL calcium-free Tyrode’s 
solution followed by 300 mL 1.0% (w/v) formaldehyde, 0.8% (w/v) picric acid in 0.1 M 
sodium phosphate buffer.  SCG and the fifth lumbar (L
.  Mechanical 
thresholds were measured with the Dynamic Plantar Aesthesiometer apparatus (Ugo 
Basile) set to apply a maximum force of 50 g at a ramp rate of 5 g/sec.  The hot plate test 
was performed at 11, 12, 13, and 14 weeks of age by measuring the response time to lick 
a hind paw with at least 10 minutes between the three measurements from each rat.  The 
Model 39D Analgesia Meter hot plate (IITC) was set at 52°C.  The tail flick test was 
performed only at 14 weeks.  Tails were blackened with ink and tested three times with a 
Tail Flick Analgesia Meter apparatus (IITC). 
5) DRG were removed and post-
fixed in the same fixative overnight at 4°C.  Ganglia were cryopreserved in antifreeze 
solution (Hoffman and Le 2004) and stored at -20°C.  Prior to sectioning, they were 
rinsed for three days in 25% (w/v) sucrose in 0.01 M phosphate buffered 0.9% (w/v) 
saline (PBS).  One DRG and one SCG from each rat were used for immunofluorescence.  
All DRG were embedded in a frozen block and all SCG were embedded in a second 
frozen block.  Both blocks were sectioned at 14 µm on a Microm HM 550 OMVP 
cryostat (Richard Allan Scientific).  Sections were dried at 37° for one hour and rinsed 
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three times with PBS.  After blocking in 10% (v/v) normal goat serum, 2% bovine serum 
albumin, 2% polyvinylpyrolidone in PBS with 0.2% (v/v) Triton X-100 (PBS-T), 
sections were incubated for four days at 4°C in primary antisera diluted in PBS-T.  
Sections of DRG were incubated in either rabbit anti-GLS (gift of N. Curthoys at 
Colorado State University) diluted to 1:10000 or rabbit anti-Nav1.8 (Sigma) diluted to 
1:4000 while SCG sections were incubated with rabbit anti-tyrosine hydroxylase (TH) 
diluted to 1:1000 (Chemicon).  Sections were rinsed three times in PBS before incubating 
in 1.0 µg/mL biotinylated goat anti-rabbit IgG (Vector Laboratories) diluted in PBS-T for 
one hour at room temperature.  Sections were rinsed twice in PBS and once in sodium 
carbonate buffered saline, pH 9.6 (SCBS) before incubating for one hour in 1.0 µg/mL 
avidin-FITC diluted in SCBS.  Sections were rinsed three times in PBS and then 
incubated for 30 minutes at room temperature in 0.5 µg/mL AlexaFluor 568-conjugated 
isolectin B4 and 300 mM DAPI diluted in PBS with 1 mM CaCl2
 Images were acquired on a BX51 epifluorescence microscope (Olympus) using a 
SPOT RT740 camera (Diagnostic Instruments).  An exposure and gain combination was 
determined empirically for each antigen in which the dimmest regions of tissue could be 
discerned visually for tracing, but the brightest regions were not oversaturated.  Three 
fields of view were captured randomly from each section of each DRG using filters for 
FITC, AlexaFluor 568, and DAPI.  All nucleated cells were analyzed in ImageJ (National 
Institutes of Health) by using the freehand selection tool to identify the cytoplasm of each 
neuron as regions of interest.  Once all ROIs for a given image were selected and added 
to the ROI manager, measurements for each cytoplasmic profile from the FITC and 
.  After three more PBS 
rinses, coverslips were apposed with ProLong Gold (Invitrogen). 
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AlexaFluor 568 images were exported to a spreadsheet for statistical analysis (Hoffman 
and Miller 2008). 
 GraphPad Prism version 5.01 was used to make graphs and perform statistical tests.  
Significant effects of NGF deprivation (5 high anti-NGF rats vs. 5 low anti-NGF rats vs. 
6 cytC rats) on thermal latencies, mechanical thresholds, hot plate responses, and 
immunofluorescence were determined with two-way ANOVA’s with post-hoc 
Bonferroni tests for multiple comparisons.  Differences in tail-flick responses were 
determined with one-way ANOVA with post-hoc Bonferroni test for multiple 
comparisons.  Graphs display means with error bars representing standard error of the 
mean (SEM).  P values less than 0.05 were considered significant.  
Results 
 The first experiment provided needed information about the duration and magnitude 
of immunologic response to the immunization protocol used (Figure 4.1A).  Of the 12 
rats immunized against cytC, four were put in a low titer group because their titers were 0 
one week after the booster immunization.  Their titers eventually started to rise at 12 
weeks, but never got higher than 16000.  Three rats were put in a medium titer group 
because they had positive serum titers at week 11, but had not reached 96000 by week 12.  
The remaining five rats were considered high titer, because they all reached a titer of 
96000 by week twelve and maintained it through week 14.  Naïve rats never showed a 
positive titer.  No significant differences in behavioral responses were noted between rats 
of different groups (data not shown).  Since cytC and 2.5S NGF are similar in molecular 
weight, we predicted a comparable immune response to NGF.  Power analysis of 
behavioral data from the first experiment indicated that at least four high anti-NGF titer 
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rats would be needed for 80% power (beta = 0.2).  In order to have enough rats with high 
anti-NGF titer, we immunized ten rats against NGF.  We determined to measure 
expression of GLS and Nav
 The responses, in seconds and grams, respectively, increased significantly between 
the pre- and post-immunization periods (Figures 4.2A and 4.2B).  The presence of high 
NGF titer had no effect on thermal latency or mechanical threshold at any of the time 
points tested.  Rats in the high NGF titer group had significantly longer response times 
for the hot plate test at 11, 12, and 14 weeks, which were approximately twice as long as 
cytC and low NGF titer rats (Figure 4.2C).  Responses of low NGF titer rats were never 
significantly different from cytC rats for the hot plate test.  There were no differences 
1.8 after three weeks of exposure to high amounts of anti-
NGF by letting the rats of the second experiment survive until they were 14 weeks old 
since anti-cytC titers remained elevated at 14 weeks in the first experiment.   
 Rats immunized against cytC for the second experiment did not show the same 
magnitude of response as the rats in the first experiment did; however, all but one rat did 
have a positive titer for anti-cytC antibodies (Figure 4.1B).  The responses to NGF 
immunization were split into high and low titer groups (Figure 4.1B).  Five rats were 
considered high titer, because they had titers of 96000 by 12 weeks and maintained the 
high titer to 14 weeks.  The remaining five rats were put into the low titer group.  All of 
the low titer rats had titers of 32000 or less at 14 weeks.  Cerebrospinal fluid of four of 
the NGF immunized rats with high titer and three of the cytC immunized rats was tested 
for presence of anti-NGF and anti-cytC respectively.  Antibody titers of cerebrospinal 
fluid were zero in all cases as previously reported (Chudler, Anderson et al. 1997). 
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among the three groups for the tail flick test at 14 weeks (data not shown); the average 
response time was between 6 and 10 seconds for all three groups. 
 The size of SCG neurons was measured by examining TH-positive neuron profiles.  
Qualitatively, SCG neurons from all rats immunized against NGF except one showed 
some degree of atrophy.  SCG from rats with high and low anti-NGF titers had decreased 
neuronal cytoplasmic area, increased number of heterochromatic nuclei (non neuronal), 
and neuronal cell loss (Figure 4.3).  The SCG's of rats immunized against cytC had a 
similar morphology to the SCG's of naive rats.  
 DRG neuron profiles were separated into small (<600 µm2) and large (>600 µm2) cell 
size populations (Figure 4.4A). Small neurons were separated further into IB4 positive 
and negative populations based on a threshold set at the minimum between two peaks of 
a frequency distribution for IB4 intensity (Figure 4.4B).  Mean gray values of the FITC 
image for each cell were used as a measure of IR.  Mean IR’s were calculated for three 
neuron populations (small IB4 positive, small IB4 negative, and large) for each rat.  GLS-
IR did not change significantly among the three groups (cytC, low NGF, high NGF) for 
any of the three cell populations even though there was a trend for GLS-IR to be lower in 
small DRG neurons of NGF-immunized rats as compared to cytC-immunized rats (Figure 
4.5 and 4.7A).  Nav1.8-IR was significantly lower in large cells as compared to small 
cells of cytC and low NGF titer rats.  Small IB4 negative DRG neurons from high NGF 
titer rats had decreased Nav1.8-IR as compared to small IB4 negative DRG neurons of 
low NGF titer and cytC rats and small IB4 positive neurons of all three groups of rats 
(Figure 4.6 and 4.7B).  There was no significant effect of NGF immunization on DRG 
neuron size for any of the three populations tested. 
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Discussion 
 The immunization protocol used in this study was very similar to that used in other 
studies (Doubleday and Robinson 1994; Doubleday and Robinson 1995; Chudler, 
Anderson et al. 1997); however, there has been little published information regarding the 
weekly antibody titer progression after the booster immunization.  We determined 
immunization efficacy and temporal progression by immunizing rats against cytC and 
monitoring serum anti-cytC weekly after the booster immunization.  A previous study 
indicated that approximately 25% of the rats immunized were high titer (Chudler, 
Anderson et al. 1997).  In our experiment, 5/12 (42%) rats were high titer.  As expected 
(Bean 2001), a peak in anti-cytC of high titer rats was observed two weeks following the 
booster immunization (Figure 1A) when the rats were 12 weeks old, and it remained 
elevated when the rats were 14 weeks old.  These results prompted us to immunize ten 
rats against NGF in the second experiment and end the study when rats were 14 weeks 
old in anticipation of having at least four rats with high anti-NGF titers.  Behavioral 
responses of naïve rats compared to rats immunized against cytC for the first experiment 
were not significantly different.  We, therefore, decided to use cytC immunized rats as 
controls for the second experiment. 
 Five of the ten NGF immunized rats were placed into a high titer group since they had 
a 96000 titer at 12 weeks that remained at 14 weeks.  The other five NGF immunized rats 
were placed in a low titer group.  Antibodies for cytC and NGF were not present in the 
cerebrospinal fluid, which indicated that any effects of immunization were due to 
peripheral actions of the antibodies and were not consequences of antibody interactions 
with the central nervous system. 
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 Although NGF deprivation did not significantly change thermal latencies or 
mechanical thresholds, both measures of sensory function were increased at 9 weeks of 
age and later time points as compared to responses at 5 weeks of age.  This effect is likely 
due to the age of the rats rather than immunizations since all three groups were similarly 
affected.  The hot plate test detected differences between the high NGF titer group but not 
the low NGF titer group versus the cytC group at 11, 12, and 14 weeks.  This is similar to 
the previous study that reported hypoalgesia when using the hot plate test in adult rats 
immunized against NGF (Chudler, Anderson et al. 1997).  Our results further support that 
there is a critical level of anti-NGF that needs to be present for hypoalgesia to occur, and 
this should be taken into consideration when evaluating cellular responses to NGF 
immunization.  The lack of change in mechanical threshold in NGF immunized rats 
indicated that NGF immunization was impairing only nociception, not all sensory 
modalities.  NGF immunization did not change responses to the tail flick test, which was 
only performed at 14 weeks because the tails had to be blackened with ink.  This would 
have hindered blood collection from the lateral tail vein during the other weeks.  The 
difference in the responses to the three thermal nociception tests (thermal latency, hot 
plate, tail flick) may reveal clues as to the mechanism of hypoalgesia induced by NGF 
deprivation.  One reason for the discrepancy may be that the thermal latency test is more 
suited for detecting changes in hyperalgesia during inflammation than hypoalgesia 
(Hargreaves, Dubner et al. 1988; Le Bars, Gozariu et al. 2001).  Other reasons may be 
that the rapid and focal radiant heating of the skin in the thermal latency and tail flick 
tests selectively activates Aδ fibers, whereas the hot plate test activates C fibers (Le Bars, 
Gozariu et al. 2001). 
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 Morphology of SCG was used to verify NGF deprivation in rats immunized against 
NGF.  High and low titer rats exhibited SCG neuron atrophy, whereas cytC immunized 
rats had SCG similar to naïve rats.  The degree of atrophy was more severe in high titer 
NGF rats than in low titer rats.  Peripheral sympathetic neurons are very dependent on 
NGF for maintenance and survival, which is why even the low titer NGF rats had SCG 
atrophy.  However, levels of anti-NGF capable of depriving SCG neurons of sufficient 
NGF, does not affect peripheral sensory neurons (Gorin and Johnson 1980).  Our results 
support these findings since low titer NGF animals showed no impairment of nociception 
but did have SCG atrophy. 
 Sensory neurons are only dependent on NGF for survival during development and 
early postnatal life (Gorin and Johnson 1979; Gorin and Johnson 1980; Johnson, Gorin et 
al. 1980; Miller, Akesson et al. 1999).  In the adult rat, NGF levels in peripheral tissues 
are thought to establish the basal nociceptive threshold through regulation of proteins 
important for nociception, such as SP and CGRP (Pezet and McMahon 2006).  Glutamate 
is released from both the peripheral (Omote, Kawamata et al. 1998; deGroot, Zhou et al. 
2000; Jin, Nishioka et al. 2006) and central terminals (Skilling, Smullin et al. 1988; 
Dmitrieva, Rodriguez-Malaver et al. 2004) of DRG neurons during nociceptive 
stimulation.  DRG neurons use GLS to convert glutamine into neurotransmitter 
glutamate, so a decrease in GLS expression may limit the amount of glutamate available 
for release by DRG neurons and decrease responses to noxious stimuli.  In the present 
study, we studied GLS-IR in several populations of DRG neurons after NGF deprivation 
to determine if basal levels of NGF are necessary for normal GLS expression.  We found 
no significant difference in the GLS-IR due to NGF deprivation, indicating that basal 
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GLS expression is not regulated by NGF.  This finding, however, does not preclude the 
possibility that increased NGF, such as that produced during inflammation, may up 
regulate GLS expression.  For instance, we found that GLS-IR is increased four days 
after intraplantar CFA injection (Hoffman, Edwards et al. 2007).  Since inhibition of GLS 
has been reported to provide analgesia (Miller, Herzog et al. 2006), it would be important 
to know if it is among the targets regulated by elevated NGF levels during inflammation 
even though basal expression does not seem to be affected by decreased NGF. 
 The voltage-gated sodium channel Nav1.8 is expressed in nociceptive neurons and 
influences the electrophysiological response properties of these cells (Djouhri, Fang et al. 
2003).  There is disagreement as to whether expression of Nav1.8 is altered after 
inflammation, which may be dependent on the inflammatory model used.  No increase in 
Nav1.8 expression occurs 72 hours after intraplantar CFA injection or at 4 or 24 hours 
after NGF injection (Okuse, Chaplan et al. 1997), whereas Nav1.8 is up regulated at four 
days after intraplantar carrageenan injection (Tanaka, Cummins et al. 1998; Black, Liu et 
al. 2004).   Basal expression of mRNA for Nav1.8 has been shown to be decreased in 
small diameter IB4 negative DRG neurons after NGF deprivation (Fjell, Cummins et al. 
1999) and the results of the present study support these findings.  The neuroanatomical 
marker IB4 is frequently used to distinguish two populations of nociceptive DRG 
neurons: peptidergic, trkA-expressing neurons (IB4-negative) from nonpeptidergic, c-
Ret-expressing neurons (IB4-positive).  IB4 preferentially labels nonpeptidergic neurons 
that respond to glial-derived neurotrophic factor (GDNF) with the c-Ret receptor.  These 
neurons do not typically contain the peptides SP or CGRP.  Nociceptive DRG neurons 
that do not label with IB4 respond to NGF with the trkA receptor and do contain SP and 
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CGRP.  Similar to Fjell et al (1999), we found that the IB4-negative population of DRG 
neurons from rats with high anti-NGF titers had decreased expression of Nav1.8, 
indicating that NGF may regulate basal expression of NGF through the trkA receptor.  
Combined with the behavioral results of this study and that of Chudler et al (1997), we 
conclude that normal levels of NGF in peripheral tissues determine nociceptive 
sensitivity, at least in part, by regulating Nav
 This study determined that basal GLS expression is not affected by NGF, but 
previous results indicate it may be important for inflammatory pain (Miller, Herzog et al. 
2006; Hoffman, Edwards et al. 2007).  Na
1.8 expression. 
 One previous study showed a decrease in DRG neuron size after NGF deprivation in 
the adult rat (Rich, Yip et al. 1984).  We found that NGF did not have a significant effect 
on the mean cross sectional area for any of the three populations of DRG neurons 
examined.  Our findings support the conclusion that NGF deprivation does not cause 
appreciable atrophy in adult DRG neurons (Gorin and Johnson 1980; Johnson, Gorin et 
al. 1982; Schwartz, Pearson et al. 1982).  
v1.8 expression was decreased in NGF 
deprived rats, indicating that the mechanism of hypoalgesia after NGF deprivation 
involves decreased expression of Nav1.8.  It is probable, however, that Nav1.8 is not the 
only down-regulated protein important for nociception in these rats.  Glutamate sensitizes 
peripheral terminals of DRG neurons (Du, Koltzenburg et al. 2001) and dorsal horn 
neurons in the spinal cord (Dougherty and Willis 1991; Dougherty, Palecek et al. 1993), 
and antagonizing glutamate receptors provides analgesia during inflammation (Jackson, 
Graff et al. 1995; Davidson, Coggeshall et al. 1997; Lawand, Willis et al. 1997).  All 
DRG neurons have the enzyme GLS for making glutamate (Miller, Douglas et al. 1993; 
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Li, Ohishi et al. 1996), yet little attention has been given to the role of this enzyme in 
pain during inflammation.  The mainstay of current pain medications are non-steroidal 
anti-inflammatory drugs (NSAIDs), which inhibit the enzymes that make prostaglandins.  
Glutamate levels increase during inflammation like other sensitizing molecules such as 
the prostaglandins.  Therefore, peripheral GLS inhibition should be investigated as a 



















Figure 4.1.  Detection of antibody titers in immunized rats.  A) Serum anti-cytC titers as 
assessed by ELISA.  Twelve rats were given an initial immunization against cytC when 
they were six weeks old and a booster immunization when they were ten weeks old.  
Immunized rats were placed into low, medium, and high titer groups.  A steady increase 
in anti-cytC serum levels was apparent after the booster immunization.  The high titer 
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group reached the peak titer at 12 weeks of age and maintained it through 14 weeks of 
age.  B) Serum anti-cytC and ant-NGF titers as assessed by ELISA.  Ten rats were 
immunized against NGF and six were immunized against cytC to serve as controls.  The 
NGF-immunized rats were place in high and low titer groups.  Anti-NGF titers increased 




Figure 4.2.  Sensory testing in immunized rats.  A) Thermal latencies of rats immunized 
against cytC or NGF.  Thermal latencies were longer at 9, 11, 12, and 14 weeks as 
compared to 5 weeks for all three groups of rats (an age effect rather than an 
immunization effect).  Immunization with NGF had no significant effect on thermal 
latencies, even after the booster immunization when anti-NGF titers were highest.  B) 
Mechanical thresholds of rats immunized against cytC or NGF.  Mechanical thresholds 
were higher at 9, 11, 12, and 14 weeks as compared to 5 weeks for all three groups of 
rats.  Immunization with NGF had no significant effect on mechanical thresholds, even 
after the booster immunization when anti-NGF titers were highest.  C) Hot plate response 
times of rats immunized against cytC or NGF.  Response times were significantly higher 
in rats with high anti-NGF titers as compared to cytC immunized rats at 11, 12, and 14 
weeks of age.  Rats with low anti-NGF titers never responded significantly different than 
cytC immunized rats.  High titer NGF rats had significantly longer response times than 
low titer NGF rats at 12 and 14 weeks.  *P<0.05; **P<0.01; ***P<0.001 
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Figure 4.3.  Superior cervical ganglion morphology in immunized rats.  Representative 
images of SCG from rats immunized against cytC (upper panels) or with high anti-NGF 
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titers (lower panels).  Immunofluorescence for TH is shown in green (right panels) and is 
merged with the blue DAPI image (left panels).  SCG neurons from rats with high anti-
NGF titers appeared atrophied as compared to SCG neurons from cytC immunized rats.  
There was also an increase in the number of DAPI stained nuclei in SCG from high anti-




Figure 4.4.  Dividing DRG neurons into subpopulations based on size and IB4 labeling.  
A) The frequency distribution for the cross sectional area (in µm2) for all 1,824 cells 
analyzed was plotted and divided into small and large cell populations using 600 µm2 as 
the dividing point.  B) The frequency distribution for the IB4 labeling intensity (mean 
gray value from ImageJ) was plotted and a threshold was placed at the minimum between 
the two peaks indicating IB4 positive and IB4 negative DRG neurons. 
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Figure 4.5.  Glutaminase immunoreactivity in dorsal root ganglia of immunized rats.  
Representative images of DRG from rats immunized against cytC (upper panels) or with 
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high anti-NGF titers (lower panels).  Immunofluorescence for GLS is shown in green 
(right panels) and is merged with the blue DAPI and red IB4 images (left panels).  GLS-
IR was not significantly affected by high anti-NGF titers.   
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Figure 4.6.  Nav1.8 immunoreactivity in dorsal root ganglia of immunized rats.  
Representative images of DRG from rats immunized against cytC (upper panels) or with 
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high anti-NGF titers (lower panels).  Immunofluorescence for Nav1.8 is shown in green 
(right panels) and is merged with the blue DAPI and red IB4 images (left panels).  
Nav1.8-IR appeared less intense in large DRG neurons as compared to small diameter 
neurons.  In addition, high anti-NGF titers decreased Nav1.8-IR in small IB4 negative 





Figure 4.7.  Quantitative image analysis of GLS- and Nav1.8-IR of DRG neurons from 
rats immunized against cytC and NGF.  A) Levels of anti-NGF had no significant effect 
on GLS in any of the three DRG neuron populations examined.  B)  Large DRG neurons 
had significantly lower Nav1.8-IR than the small DRG neurons and the IB4 negative 
neurons had significantly lower Nav1.8-IR than IB4 positive neurons.  Rats with high 






Peripheral inhibition of glutaminase reduces spinal Fos expression during 
inflammation 
Abstract 
Levels of the excitatory amino acid glutamate are increased in inflamed tissues.  
Glutamate sensitizes peripheral axons of primary afferent neurons during inflammation 
leading to decreased firing threshold and hyperexcitability.  One proposed source of 
glutamate is the primary afferent itself.  Antagonizing glutamate receptors on peripheral 
axons of primary afferents during inflammation provides analgesia in animals and 
humans.  The enzyme glutaminase is used by primary sensory neurons to convert 
glutamine to glutamate.  Peripheral inhibition of glutaminase with 6-diazo-5-oxo-L-
norleucine (DON) provides long lasting analgesia during inflammation.  In this study, we 
measured the effects of glutaminase inhibition on carrageenan induced spinal Fos 
expression.  Rats were given intraplantar injections of carrageenan and treated locally 
with either vehicle or DON.  After three hours of inflammation, hind paw swelling and 
spinal expression of Fos were examined.  CellProfiler was used to automate Fos nuclei 
counting in five laminar groupings in the spinal cord (I-II, III-IV, V-VI, VII-IX, X).  
Carrageenan increased hind paw thickness by ~70% and spinal Fos expression in 
superficial (I-II) and deep (V-VI) laminae by 10-fold and 5-fold, respectively.  Treatment 
with DON reduced hind paw swelling by ~13% and suppressed Fos expression in the 
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laminae I-II by ~54%, but not the deep laminae.  Our results further support the notion of 
glutamate as a peripheral inflammatory mediator and indicate that glutaminase should be 
considered as a novel therapeutic target for treatment of inflammatory pain. 
Introduction 
Exogenous glutamate excites and sensitizes peripheral axons of primary afferent 
neurons (Du, Koltzenburg et al. 2001), and it is generally accepted that glutamate is 
involved in the sensitization of primary afferents during inflammation (Carlton 2001) 
through both ionotropic (Carlton, Hargett et al. 1995; Zhou, Bonasera et al. 1996; 
Davidson, Coggeshall et al. 1997)and metabotropic (Bhave, Karim et al. 2001) glutamate 
receptors.  The source of endogenous glutamate that interacts with primary afferents is 
not clear, although a probable candidate is the peripheral terminal itself.  Antidromic 
stimulation of the sciatic nerve increases glutamate concentrations in peripheral tissues, 
indicating a neural source of glutamate (deGroot, Zhou et al. 2000; Jin, Nishioka et al. 
2006).  Furthermore, increases in peripheral glutamate concentration after capsaicin 
stimulation are attenuated by local morphine (Jin, Nishioka et al. 2006), which suggests 
that glutamate is released by heat sensing nociceptors.  Increased glutamate 
concentrations resulting from inflammation (Omote, Kawamata et al. 1998; Lawand, 
McNearney et al. 2000) can be diminished by nerve block (Lawand, McNearney et al. 
2000), which again suggests the primary afferent as the source of glutamate.  Lastly, 
peripheral terminals of primary afferent neurons are immunoreactive for vesicular 
glutamate transporters (Brumovsky, Watanabe et al. 2007) and have varicosities that 
contain small clear vesicles akin to those that contain glutamate in the central nervous 
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system (Kruger, Kavookjian et al. 2003).  These studies, therefore, support the idea of 
glutamate autostimulation of nociceptive afferent fibers. 
Injection of carrageenan into the plantar surface of the rat hind paw increases the 
expression of c-fos mRNA (Draisci and Iadarola 1989) and Fos protein (Honore, 
Buritova et al. 1995) in the lumbar spinal cord.  Many analgesics attenuate the Fos 
increase induced by carrageenan, which indicates that Fos expression is a measure of 
activation in pain pathways and can serve to quantitate analgesia (Coggeshall 2005).  
Non-steroidal anti-inflammatory drugs (NSAIDs) decrease the formation of inflammatory 
mediators that can sensitize primary afferents (Popp, Haussler et al. 2008) by inhibiting 
the enzyme cyclooxygenase (COX).  Peripheral inhibition of COX suppresses 
carrageenan induced Fos expression (Buritova and Besson 1998).  If glutamate is to be 
considered among the molecules that sensitize primary afferent fibers during 
inflammation, then a similar approach would be to target the enzyme that synthesizes 
neurotransmitter glutamate from the precursor glutamine, glutaminase (GLS).  We have 
previously shown that the irreversible GLS inhibitor, 6-diazo-5-oxo-L-norleucine (DON), 
provides long term analgesia in a dose dependent manner (Miller, Herzog et al. 2006) and 
that GLS expression is increased (Hoffman, Edwards et al. 2007) in the complete 
Freund’s adjuvant (CFA) monoarthritis model.  In the present study, we use spinal Fos 
expression to quantify the analgesic effect of DON on carrageenan induced hind paw 
inflammation.  Our goal is to determine if glutamate that sensitizes peripheral terminals is 





Sprague-Dawley rats (n = 15; 200-300 g) were housed on a 12 hour light: 12 hour 
dark cycle and given free access to food and water.  Procedures were conducted 
according to guidelines from the National Institutes of Health (NIH 2003) and were 
approved by the Oklahoma State University Center for Health Sciences Institutional 
Animal Care and Use Committee.  All appropriate efforts were made to minimize 
discomfort and the number of animals used in this study. 
To test the effects of DON on carrageenan-evoked spinal Fos expression, rats (n=6) 
were injected with 10 µmol/25 µL DON (Sigma) in 0.01 M sodium phosphate buffered 
0.9% (w/v) saline (PBS) in the right hind paw one day before being injected with 10 
µmol DON in 100 µL of 1% (w/v) λ-carrageenan (Sigma) diluted in PBS.  This dose of 
DON was chosen based on previous behavioral experiments (Miller, Herzog et al. 2006).  
Controls consisted of rats injected with vehicle (PBS) and carrageenan (n=5) in the same 
manner and naïve rats (n=4).  Three hours after carrageenan injection, hind paw 
metatarsal thickness was measured with calipers (Mitutoyo) to the nearest 0.05 mm.  All 
rats were anesthetized with 2.5% (w/v) Avertin and xylazine and then transcardially 
perfused with 75 mL PBS followed by 325 mL 4% formaldehyde in 0.1M sodium 
phosphate buffer.  L4 spinal cord segments were dissected and post fixed for four hours 
at 4°C and then cryoprotected in 30% sucrose (w/v) for two days.  Serial 20 µm frozen 
sections were cut and thaw mounted to slides.  Sections were dried at 37°C for one hour 
and rinsed three times with PBS.  After being blocked in 5% (v/v) NGS diluted in PBS 
with 0.25% Triton X-100 (PBS-T), sections were incubated overnight at 4°C in rabbit 
anti-Fos (Ab-5 Calbiochem) diluted 1:8000 in the blocking solution.  Sections were 
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rinsed five times in PBS and incubated for two hours at room temperature in biotinylated 
goat anti-rabbit (Vector Laboratories) diluted to 1.0 µg/mL in PBS-T.  After three PBS 
rinses, the sections were incubated for one hour at room temperature in Vectastain ABC 
reagent (Vector Laboratories) prepared as per the manufacturer’s instructions.  Sections 
were rinsed two times in PBS and once in tris-buffered saline, pH 7.6 (TBS) before 
incubating for five minutes at room temperature in 3,3’-diaminobenzidene 
tetrahydrochloride (Sigma) diluted to 10 mg/24 mL in TBS with 0.5% hydrogen 
peroxide.  Sections were rinsed three times with PBS to stop the reaction and dehydrated 
in an alcohol series (50%, 70%, 90% × 2, 100% × 2).  Sections were cleared in xylene 
twice and coverslipped with Permount (Fisher). 
Ten sections from each rat were photographed using the 4X objective on a BX51 
microscope (Olympus) with a SPOT RT740 camera (Diagnostic Instruments).  Laminar 
groupings I-II, III-IV, V-VI, VII-IX, and X (Molander, Xu et al. 1984) on the side 
ipsilateral to hind paw injection were traced manually with a Cintiq 21UX interactive pen 
display (Wacom) in ImageJ (NIH).  Traced laminar groupings were made into binary 
mask images with white laminar groupings on a black background.  Fos positive nuclei 
were identified automatically and counted in each image by CellProfiler (Broad Institute 
Imaging Platform) (Carpenter, Jones et al. 2006) using the binary mask images to obtain 
Fos positive nuclei counts per laminar grouping.  The CellProfiler pipeline used is 
summarized in Table 5.1. 
Hind paw thickness measurements were compared with a two-way ANOVA with the 
fixed factors being hind paw (contralateral or ipsilateral to injection) and treatment 
groups (naïve, PBS, DON).  Numbers of Fos-positive nuclei also were compared with 
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two-way ANOVA but with fixed factors being laminar groups (I-II, III-IV, V-VI, VII-IX, 
and X) and treatment groups.  Multiple comparisons were made with Bonferroni post-
tests.  P values less than 0.05 were considered significant.  Values are reported as mean ± 
standard error of the mean. 
Results 
Intraplantar carrageenan injection elicited an inflammatory response that caused 
significant swelling (~70% increase) of the metatarsal thickness in the ipsilateral hind 
paw (8.4±0.4 mm) versus the naïve rats (4.9±0.1 mm; Figure 5.1).  Pretreatment and co-
injection with DON, the GLS inhibitor, had a small but significant effect (~13% 
decrease) on carrageenan mediated hind paw swelling (7.3±0.3 mm), but it did not reduce 
hind paw thickness to that of naïve rats.  Automated counting of Fos nuclei per laminar 
grouping provided a strictly objective criteria for identifying nuclei labeled for Fos that 
was consistent for all images analyzed.  After laminar groupings were traced on all 
images, CellProfiler took an average of 14.1 seconds to process each image through the 
pipeline (Table 5.1).  Naïve rats had less than five Fos nuclei per laminar grouping.  
Carrageenan significantly increased the number of Fos nuclei in ipsilateral laminae I-II 
(23±5) and laminae V-VI (28±4), without significantly affecting the number of Fos 
nuclei in other laminae (Figures 5.2 & 5.3).  Pretreatment and co-injection with DON 
significantly decreased (~54%) the number of Fos nuclei in ipsilateral laminae I-II 
(11±1), but not laminae V-VI (22±3), as compared to PBS treated rats.  There were still 
significantly more Fos nuclei in laminae I-II and laminae V-VI in DON treated rats than 




Peripheral processes of primary afferent neurons have been implicated as the source 
of elevated glutamate released during inflammation (Carlton 2001).  We hypothesized 
that inhibiting the enzyme GLS at the site of inflammation would suppress carrageenan 
induced Fos expression in spinal cord.  Our finding that peripheral DON injection was 
able to suppress Fos expression in spinal cord supports the long-lasting analgesic effects 
of DON observed in the CFA inflammation model (Miller, Herzog et al. 2006).  
Antagonism of NMDA glutamate receptors systemically  suppresses spinal Fos 
expression during peripheral inflammation throughout all laminar groupings in spinal 
cord, even ventral horn, but does not affect hind paw edema (Chapman, Honore et al. 
1995).  Such findings indicate that effects of systemic NMDA antagonism are mediated 
primarily acting in central nervous system.  Peripheral NMDA antagonism  also 
suppresses spinal Fos expression by ~35% during inflammation (Wang, Liu et al. 1997), 
which indicates glutamate sensitization of primary afferents at least partially accounts for 
increased spinal Fos expression.  In addition to glutamate, intraplantar antagonism of two 
other sensitizing factors, the enzyme COX (Buritova and Besson 1998) and the 
bradykinin B2 receptor (Buritova, Chapman et al. 1997), also reduces carrageenan-
induced spinal Fos expression.  Peripheral COX inhibition with the highest dose of 
flurbiprofen resulted in a 52±5% suppression of the increase in Fos expression in laminae 
I-II and a 62±2% suppression in laminae V-VI (Buritova and Besson 1998).  Antagonism 
of the B2 receptor with the highest dose of HOE140 resulted in a 51±6% suppression of 
the increase in Fos expression in laminae I-II and a 48±7% suppression in laminae V-VI 
(Buritova, Chapman et al. 1997).  The highest doses of flurbiprofen and HOE140 also 
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decreased hind paw edema by 67±7% and 41±3%, respectively.  COX is already the 
target of many analgesics, and bradykinin antagonism is being considered as a new 
analgesic strategy (Chen and Johnson 2007; Kuduk and Bock 2008).  The finding that 
GLS inhibition has similar effects on Fos expression in laminae I-II to COX and 
bradykinin inhibition supports glutamate as a sensitizer of primary afferents and suggests 
GLS as a potential therapeutic target for inflammatory pain.    The smaller anti-
inflammatory effect of DON as compared to flurbiprofen and HOE140 may account for 
the lack of a significant effect on Fos suppression in laminae V-VI.  Although much 
evidence points toward the primary afferent as the source of increased glutamate during 
inflammation, other peripheral cell types cannot be ruled out.  Keratinocytes (Nguyen and 
Keast 1991), fibroblasts (Sarantos, Abouhamze et al. 1994), and white blood cells 
(Newsholme, Crabtree et al. 1985) all have GLS and may have a role in producing 
glutamate that acts on primary afferent fibers. 
Primary afferent nociceptors have an efferent role during inflammation (Sann and 
Pierau 1998).  Following transection of the sciatic nerve or neonatal destruction of 
capsaicin sensing DRG neurons, plasma extravasation during inflammation is markedly 
attenuated (Jancso, Kiraly et al. 1977).  The component of inflammation contributed by 
the primary afferent has been called neurogenic inflammation, and it is presumed to be 
mediated by release of the neuropeptides substance P and calcitonin gene related peptide  
which results in vasodilatation and edema (Alvarez, Cervantes et al. 1988; Donnerer, 
Schuligoi et al. 1992).  Exogenous glutamate causes overt nociception and swelling that 
can be blocked by antagonizing substance P (Beirith, Santos et al. 2003).  Glutamate, 
therefore, may cause release of SP and CGRP from primary afferents.  In this study, a 
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13% decrease in hind paw edema was observed after DON inhibition of carrageenan 
inflammation.  We hypothesize that decreasing the concentration of glutamate with DON 
may suppress the amount of substance P released, decreasing the neurogenic component 
of inflammation.   
Antagonism of glutamate receptors at the periphery provides analgesia during 
inflammatory pain models (Jackson, Graff et al. 1995; Davidson, Coggeshall et al. 1997; 
Bhave, Karim et al. 2001; Du, Zhou et al. 2003).  Such analgesic effects have been 
attributed to glutamate receptors on the primary afferents themselves (Sato, Kiyama et al. 
1993; Carlton, Hargett et al. 1995; Carlton and Coggeshall 1999; Kinkelin, Brocker et al. 
2000).   Exogenous glutamate injection causes pain and vasomotor responses in humans 
as well, and glutamate receptor antagonists can provide analgesia (Warncke, Jorum et al. 
1997).  In light of this information, our study further indicates that antagonism of 
glutamate at the periphery is a viable pain therapy, and we propose the enzyme GLS as 





Figure 5.1.  Effects of peripheral GLS inhibition on carrageen induced hind paw swelling.  
Intraplantar carrageenan injection caused a unilateral inflammation of the hind paw.  













Figure 5.2. Representative images of spinal Fos immunohistochemistry after carrageenan 
induced inflammation.  Carrageenan injection with PBS treatment induced Fos 
expression in superficial (I-II) and deep laminae (V-VI) of the ipsilateral spinal cord 
dorsal horn (top).  Inhibition of GLS with DON decreased the number of carrageenan 
induced Fos nuclei in superficial laminae (54%) without affecting the number of Fos 







Figure 5.3.  Effects of peripheral GLS inhibition on carrageen induced  Fos expression. 
Automated counting of Fos nuclei for five laminar grouping revealed significant 
increases in Fos expression in the superficial (I-II) and deep (V-VI) dorsal horn after 
carrageenan injection with PBS treatment.  Treatment with DON significantly reduced 







LoadImages loads image pairs (binary mask of laminae and original) 
IdentifyPrimAutomatic identifies laminae as objects from binary mask image 
InvertIntensity inverts intensity of original so Fos nuclei are white 
ApplyThreshold sets all gray values below a certain intensity to black 
IdentifyPrimAutomatic identifies Fos nuclei by shape and intensity 
MeasureObjectAreaShape obtains area measurements for laminae and nuclei 
MeasureObjectIntensity obtains intensity measurements for laminae and nuclei 
Relate counts number of Fos nuclei within each laminar 
grouping 
ExportToExcel exports all measurement data to Excel spreadsheet 
 
Table 5.1.  Summary of pipeline used in CellProfiler for automated detection and 
counting of Fos nuclei in images of spinal cord sections.  Manual identification of 
laminar groupings was required prior to using the CellProfiler software.  Each module 







Novel strategies to manage inflammatory pain could improve the quality of life for 
those suffering intractable pain and the health of those experiencing negative side effects 
of current analgesics.  The advantages of targeting nociceptive neurons in the peripheral 
ganglia are that: (1) they are the beginning of the “pain pathway”, (2) they are outside of 
the CNS, and (3) they uniquely express specific proteins used for nociception.  This 
allows for fewer side effects and the potential for topical drug application at the site of 
inflammation.  Identification of such molecular targets requires precise characterization 
of protein expression in nociceptive neuron populations.  Due to differences in laboratory 
technique, reported distributions for many proteins vary.  These issues were addressed in 
Chapter 2.  By comparing concentrations of formaldehyde and picric acid in the fixative 
used for immunofluorescence studies, we determined that each antigen-antibody pair has 
an optimal concentration of these two fixatives that gives maximal sensitivity.  We 
concluded that such optimization should be performed when determining antigen 
distribution. 
Since its accidental discovery as a fixative in the late nineteenth century (Blum 1893), 
formaldehyde has remained the most popular fixative used for both histopathology and 
basic science (Fox, Johnson et al. 1985).  It has long been recognized, however, that 
formaldehyde fixation is not optimal for preserving tissue antigenicity (Hopwood 2002).
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Our current understanding of the mechanism of formaldehyde fixation dates back to the 
1940s, when it was shown that formaldehyde cross-links amino acid residues in proteins 
(Fraenkel-Conrat and Olcott 1948; Fraenkel-Conrat and Olcott 1948; Fraenkel-Conrat 
and Mecham 1949).  Unlike glutaraldehyde (C5H8O2), which is a dialdehyde, 
formaldehyde (CH2O) has only one reactive group (Figure 6.1).  In aqueous solution, 
formaldehyde exists mainly as its monohydrate (CH4O2), methylene glycol (Le Botlan, 
Mechin et al. 1983), that can oligomerize and/or form methylene cross bridges between 
amino acids in proteins (Puchtler and Meloan 1985).  It is postulated that when amino 
acids are cross-linked with one another, antigens are “masked” and are unavailable for 
interaction with antibodies (Sompuram, Vani et al. 2004).  Certain techniques called 
antigen retrieval have been developed to “unmask” antigens after formaldehyde fixation 
and reestablish immunolabeling (Shi, Key et al. 1991).  The success of such techniques is 
variable and there is not a single technique that works for all antigen-antibody 
combinations (Shi, Liu et al. 2007).  Our results indicate a way to circumvent the need for 
antigen retrieval techniques by optimizing the formaldehyde concentration in the fixative 
in order to obtain maximal antigen detection sensitivity, while maintaining adequate 
fixation by addition of other fixative component (picric acid).  Our results are more likely 
to influence basic science research where greater control over fixation methods is 
possible.  This could lead to more accurate determinations of antigen distribution in not 
just the rat dorsal root ganglion, but any tissue used for basic science research.  Once the 
susceptibility of antigens processed routinely in pathology laboratories is known, specific 
concentrations of formaldehyde may become standard for certain antigen labeling 
protocols in the clinical setting as well. 
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Even less is known about the mechanism of picric acid fixation, but it is thought to be 
a precipitant/coagulant fixative that denatures proteins (Polak and Van Noorden 2003).  
Picric acid has three nitro groups (Figure 6.1) that react with histones and basic proteins 
and forms crystalline picrates with free amino acids.  Tissues, therefore, retain little 
affinity for basic dyes and exhibit prominent shrinkage (Hopwood 2002).  Usually, picric 
acid is used in combination with other fixatives in both the clinical and basic science 
research settings.  A popular picric acid-containing fixative was introduced in 1897 by 
Pol Andre Bouin for optimal viewing of gametes in the rat testis and has since been 
referred to as Bouin’s fluid.  Subsequent picric acid fixatives also were named after those 
that introduced them (i.e., Rossman’s, Gendre’s, and Zamboni’s), and were found to be 
advantageous for viewing of carbohydrates (Hopwood 2002).  Qualitative comparisons 
such as that done for GLS in brain (Kaneko, Itoh et al. 1989) have been performed to 
determine if picric acid has an effect on immunoreactivity.  Our study in Chapter 2 
showed that picric acid either had no effect on immunoreactivity or increased it, but it 
never had a negative effect like formaldehyde.  Adding picric acid increased detection 
sensitivity for Nav
The neurotransmitter glutamate is released from peripheral and central terminals of 
DRG neurons, but the distribution of the synthetic enzyme for glutamate, GLS, was not 
clear.  Very few studies had investigated the distribution of GLS in the DRG, and there 
was not a consensus among those that had.  A few reports had determined that 30-40% of 
1.8 and TRPV1, and it may have a similar effect for other antigen-
antibody combinations.  As with formaldehyde, it would be beneficial to optimize picric 
acid concentration in the fixative used for preservation of tissue used for research or 
clinical diagnosis. 
 133 
DRG neurons expressed GLS, and these were mainly small diameter neurons.  Other 
studies had determined that 80% or more of DRG neurons expressed GLS, regardless of 
size.  The main difference between the methodologies in these two sets of studies was the 
fixative used.  As part of the optimization study in Chapter 2, we found that sensitivity 
for GLS detection was optimal when low formaldehyde was used, and that picric acid 
concentration did not have any effect.  These findings indicated that the latter group of 
studies was closer to describing the true distribution of GLS in the DRG, which we 
determined was ubiquitous among DRG neurons.  Our results are supported by the need 
of all DRG neurons to synthesize glutamate for release from central terminals (Figure 
6.2). 
Glutamate concentrations increase in inflamed tissue and sensitize peripheral 
terminals of DRG neurons.  In addition, glutamate concentrations in spinal cord dorsal 
horn increase following noxious inflammatory stimulation.  Sensitization can regulate the 
expression of proteins in DRG neurons, which accounts for long-term changes in 
threshold and excitability.  Prior to our studies, there was no information regarding 
glutamate metabolism in DRG neurons during inflammation.  In Chapter 3, we 
investigated expression of the enzyme GLS, which is responsible for neurotransmitter 
glutamate synthesis, in a long-term inflammatory pain model.  We determined that GLS 
expression is elevated after four days of inflammation in all DRG neurons and remains 
elevated in the small DRG neuron population after eight days of inflammation.  We 
presume that increased GLS expression could supply the elevated amounts of glutamate 
released at the peripheral and/or central terminals of DRG neurons (Figure 6.3). 
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Many of the expression changes that occur in DRG neurons during inflammation are 
the result of retrograde NGF signaling.  NGF binds to membrane receptors on peripheral 
terminals, is endocytosed, and transported on microtubules toward the cell body in the 
DRG in signaling endosomes (Delcroix, Valletta et al. 2003).  The signaling cascade 
proteins associated with the endosomes lead to regulatory changes of gene expression at 
the cell body (Figure 6.4).  For instance, TRPV1’s dual promoter system has been found 
to be positively regulated by NGF (Xue, Jong et al. 2007).  It is postulated that basal 
expression of proteins upregulated during inflammation is under the control of 
peripherally produced NGF.  Sequestering NGF with anti-NGF antibodies deprives DRG 
neurons of their peripheral source of NGF and causes hypoalgesia (Chudler, Anderson et 
al. 1997).  The exact mechanism for this hypoalgesia is not certain, but one study has 
implicated that decreased Nav
Since glutamate is a sensitizer of nociceptor peripheral terminals and it is produced in 
elevated amounts in inflamed tissues, it would be advantageous to know how it is being 
produced.  The results of Chapter 3 indicated that it may be made by neuronal GLS, 
1.8 expression is involved (Fjell, Cummins et al. 1999).  
Since GLS was found to be upregulated during inflammation in Chapter 3, we decided to 
determine if NGF deprivation via autoimmunization decreased GLS expression in 
Chapter 4.  We found that basal GLS expression is not affected by NGF deprivation 
(Figure 6.5).  NGF production is increased in inflamed tissues, making more NGF 
available for retrograde transport to the cell body in the DRG.  These elevated amounts of 
NGF may still account for the upregulation of GLS that we observed in Chapter 3.  
Further experiments, where NGF is blocked during inflammation will need to be 
performed to determine if this is the case (see future directions section below). 
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which is upregulated during inflammation.  Cyclooxygenase (COX) is another enzyme 
that makes sensitizing molecules (prostaglandins), and it is also upregulated in inflamed 
tissues (Schuligoi, Ulcar et al. 2003).  Inhibition of COX with NSAIDs is a first choice 
treatment for many types of inflammatory pain and reduces Fos expression in spinal cord 
during inflammatory stimulation in animals.  If GLS can also reduce Fos expression in 
spinal cord, the argument for GLS as a novel analgesic target will be strengthened.  In 
Chapter 5, we showed that peripheral inhibition of GLS during carrageenan induced hind 
paw inflammation attenuates the usual increase in spinal cord Fos expression.  We used a 
glutamine analog called DON (Figure 6.6) to inhibit GLS in the periphery and used Fos 
expression in spinal cord as a measure of analgesic efficacy.  It should be noted that Fos 
expression has limitations, and inferences that elevated spinal Fos expression indicates 
increased electrical activity in spinal neurons should not be made without 
electrophysiological confirmation.  Despite the limitations of quantifying spinal Fos 
expression, a review on spinal Fos expression as a marker for nociception referenced 485 
articles (Coggeshall 2005), and the majority of cited references were original reports that 
used Fos immunohistochemistry on spinal cord sections during some form of noxious 
stimulation.  Although studies of Fos expression may not be reliable at indicating precise 
electrical activity, the vast number of Fos studies allows for relative comparisons to be 
made.  Experimental analgesics that have been proven by other methodologies and 
analgesics used to treat clinical pain provide benchmarks for comparison of novel 
analgesics.  For instance, peripheral inhibition COX with the highest tested dose of 
flurbiprofen suppresses the increase in Fos expression by 52±5% in laminae I-II and by 
62±2% in laminae V-VI three hours after carrageenan induced inflammation.  Peripheral 
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inhibition of the NMDA glutamate receptor with the highest dose of MK-801 suppresses 
the increase in total Fos expression by ~35% (counting was not performed for individual 
laminar groupings) one hour after formalin induced inflammation.  GLS inhibition with 
DON suppressed the increase of Fos expression in laminae I-II by 54% after three hours 
of carrageenan induced inflammation (Figure 6.7).  However, GLS inhibition had no 
effect on Fos expression in laminae V-VI.  The magnitude of the effect of DON on Fos in 
the superficial dorsal horn, therefore, was similar to that of COX inhibition.  Coupled 
with previous evidence that peripheral GLS inhibition reduces hyperalgesia during a CFA 
inflammatory pain model, this new finding further supports the idea that GLS inhibition 
may be a successful analgesic strategy for inflammatory pain.  However, if GLS 
inhibition becomes an analgesic strategy, measures must be taken to minimize effects on 
the central nervous system since all glutamatergic and GABAergic CNS neurons use 
glutaminase.  We support the use of GLS inhibitors topically to decrease the 
concentration of drug in the CNS. 
Future directions 
In this study, GLS expression was shown to be increased during inflammation 
(Chapter 3; Figure 6.3), but its basal expression was not affected by NGF depletion 
(Chapter 4; Figure 6.5).  NGF is implicated in the upregulation of proteins in DRG 
neurons during inflammation, and the results of this study do not rule out the possibility 
that NGF is responsible for the upregulation of GLS during inflammation.  A future 
direction, therefore, should be to examine GLS expression in DRG neuron 
subpopulations during a long-term inflammation in chronically NGF deprived rats.  The 
autoimmunization protocol used in Chapter 4 should be performed, and rats that develop 
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high anti-NGF titers and control rats immunized against cytC should be given an 
injection of CFA in the hind paw as in Chapter 3.  If the elevated NGF present during 
inflammation is responsible for GLS up-regulation, then the NGF deprived rats should 
have lower GLS expression as compared to rats immunized against cytC.  In addition, it 
would be expected that the NGF autoimmunization might be an effective “pain vaccine” 
in the sense that it may be able to prevent the development of hyperalgesia. 
Although GLS is widely expressed throughout the body (i.e., kidney, intestine, skin, 
immune system, CNS), topical application of GLS inhibitors to inflamed areas will limit 
the negative side effects.  The COX inhibitor trolamine and the TRPV1 agonist capsaicin 
have already been marketed as analgesic topical creams (Aspercreme® and Arthricare®, 
respectively), indicating the effectiveness of topical analgesics for treatment of 
inflammatory pain in deeper tissues such as muscles and joints.  The GLS inhibitor DON 
has been administered locally by injection into the rat hind paw (Chapter 5).  While this 
is convenient for experimentation with rats, it does not represent how the inhibitor will be 
used clinically.  Another future direction should, therefore, be to formulate DON in a 
topical cream that can be applied to the hind paw skin prior to or during inflammation 
and measure behavioral responses and spinal Fos expression.  A novel GLS inhibitor, bis-
2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (Robinson, McBryant et al. 
2007), should be tested alongside DON to compare efficacy and potency.  This 
information could lead to the design of more GLS inhibitors with optimal 





    
 
formaldehyde  glutaraldehyde   picric acid 
Figure 6.1.  Chemical structures of fixative components.  Formaldehyde monomer (left) 
has only one functional group as compared to the dialdehyde, glutaraldehyde (middle).  






Figure 6.2.  Summary of Chapter 2 findings.  Two DRG neurons are depicted.  The lower 
one is a small diameter nociceptive neuron with a bare nerve ending peripheral process 
and a central process that terminates in the spinal cord dorsal horn.  The upper one is a 
large diameter touch responsive neuron with an encapsulated (Pacinian corpuscle) ending 
peripheral process and a central process that terminates in the medulla.  Both neurons use 
glutamate for neurotransmission.  The nociceptive neuron uses glutamate at both the 
peripheral and central terminals, while the large diameter neuron uses glutamate on the its 
central terminal only.  GLS, the enzyme that synthesizes glutamate, was localized in all 
DRG neurons in Chapter 2.  However, small neurons had relatively higher expression 




Figure 6.3.  Summary of Chapter 3 findings.  Inflammation was induced in the rat hind 
paw.  NGF and glutamate levels are increased in inflamed tissue.  Glutamate 
concentrations increase in dorsal horn of spinal cord during peripheral inflammation and 
Fos expression is increased in the nuclei of dorsal horn neurons.  We found that GLS 
expression was elevated in small diameter DRG neurons after four and eight days of 
inflammation.  Up-regulation of GLS may account for increased glutamate 
concentrations in the periphery and spinal cord.  NGF is retrogradely transported to the 
cell body and is known to affect the expression of genes important for nociception (see 
Figure 6.4).  GLS up-regulation may be among the genes under positive regulatory 
control of the high NGF levels during inflammation.  Further experiments are necessary 





Figure 6.4.  The role of NGF in peripheral sensitization.  NGF is involved in post-
translational changes to proteins already present in the peripheral terminal as well as 
increasing expression of proteins by retrograde transport to the cell body in signaling 
endosomes.  Basal levels of NGF may regulate the sensitivity of nociceptive DRG 
neurons by regulating the expression of proteins important for pain sensation (Hefti, 
Rosenthal et al. 2006). 
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Figure 6.5.  Summary of Chapter 4 findings.  Immunization with NGF produced a 
constant level of anti-NGF antibodies that could bind to NGF and prevent its endocytosis 
by primary afferent terminals and subsequent retrograde transport.  High anti-NGF levels 







         
glutamine  glutamate  DON 
Figure 6.6.  Chemical structures of glutamine, glutamate, and DON.  DON is a glutamine 
analog, and it is identical in structure to glutamine except for the 6-diazo group that 







Figure 6.7.  Summary of Chapter 5 findings.  Hind paw inflammation was induced while 
simultaneously blocking GLS with DON.  We observed a suppression of Fos up-
regulation in dorsal horn of spinal cord as compared to inflammation alone (represented 
by decreased font size).  Previously, DON inhibition has been shown to be an effective 
analgesic.  We hypothesize that GLS inhibition with DON decreased peripheral 
glutamate levels, which resulted in less peripheral sensitization and fewer action 
potentials reaching the spinal cord (less glutamate release onto dorsal horn neuron).  We 
postulate that the suppression of Fos expression in the spinal cord was due to reduced 
electrical activity in dorsal horn neurons, but electrophysiological data are required to 
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User-friendly method of immunofluorescence quantitation in individual DRG neurons 
Neurons regulate their function by altering the activity and expression of proteins. 
The latter is commonly studied by immunoblotting lysates from the cells of interest and 
normalizing to a loading control with densitometry. Immunoblotting works well when 
studying cell populations of high purity such as in culture. However, in vivo studies often 
involve neural tissue of heterogeneous cell types. If a subpopulation of cells in a tissue 
alters expression of a target protein, the magnitude of the effect detected by 
immunoblotting will be diluted by the cells that do not alter expression. This dilution 
effect may go so far as to mask the changes in expression that take place. If neural tissue 
is subjected to histological sectioning instead of homogenization, immunofluorescence 
microscopy can be used to label specific proteins. Since immunofluorescence microscopy 
uses a similar protocol to immunoblotting once the tissue has been processed, it may be 
used to study protein expression if proper optimization is performed. Although 
immunofluorescence microscopy is used frequently in both medicine and research, the 
goal is rarely to study the expression level of proteins on a per cell basis. This is likely 
due to the variability of labeling intensity under non-optimized conditions and the 
architecture of many neural tissues, which makes identification of individual cells 
difficult. The dorsal root ganglion (DRG) is comprised of spherical to ellipsoidal sensory 
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neurons, each surrounded by a capsule of satellite glial cells. The DRG is very amenable 
to immunofluorescence microscopy for measurement of protein expression at the level of 
individual cells because of its architecture and heterogeneous neuron populations that 
serve different sensory modalities. In this appendix, we demonstrate a streamlined 
protocol for measuring immunofluorescence of individual cells using free image analysis 
software (Image J, NIH). We detail the steps involved in tracing neuron profiles, 
measuring immunofluorescence.  This method could be used to elucidate protein 
expression changes not previously detectable in vivo and localize the changes to specific 
subpopulations of nociceptive DRG neurons based on phenotypic markers that indicate 
function. Understanding which neurons of the DRG regulate expression of specific 
proteins during pathological conditions such as inflammatory or neuropathic pain could 
identify novel targets for the treatment of pain. 
1. Go to http://rsb.info.nih.gov/ij/, download and install the newest version of ImageJ. 
2. Open Image J.  For basic operation of ImageJ, consult the “Documentation” link on 
their website. 
3. Open a grayscale image of the field from the color channel containing the most 
universal labeling (whichever antibody labels the most cells). 
4. Go to Image > Zoom > View 100% and then resize the image window to fill your 
screen.  You can use the “scrolling tool” (looks like a hand) to move the image 
around so that you can see all of the cells. 
5. If you want the output measurements to be in a real unit (like micrometers) and you 
know the conversion factor for the microscope and objective you used to take the 
image then go to Analyze > Set Scale. 
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6. Go to Analyze > Set Measurements and select the measurements you want to obtain 
from each Region of Interest (ROI). 
7. Using the freehand selections tool to trace the outline of a cell against the 
background. 
8. While holding Alt, trace the nucleus.  This will remove the nucleus from the ROI, 
making it into a ‘donut’ shape. 
9. Press ‘t’ to add the cytoplasmic profile to the ROI Manager. 
10. Within the ROI Manager window, press the ‘Show All’ button. 
11. Repeat steps 7 through 9 for all nucleated cells on the image.  You should now see the 
outlines overlays on the image for all of the cytoplasmic profiles that you traced. 
12. Press the ‘Measure’ button in the ROI Manager window.  This will cause a Results 
window to appear. 
13. Select all of the data in the Results window.  Cut and paste them to a spreadsheet. 
14. Press the ‘Save’ button in the ROI Manager window to save the outline overlays as a 
.zip archive folder. 
15. If you have an image from another color channel from the same field of view, open it 
and close the first image. 
16. Make sure your ROI Manager window still has the ROIs listed and press the ‘Show 
All’ button, which will put the outline overlays on the second image.   
17. Repeat steps 12 and 13. 
18. If you have images from additional color channels from the same field of view, repeat 
steps 15 through 17. 
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19. Now you have quantitative data for individual cells, which you can use to measure 
changes in intensity among cells of certain sizes, or, if you had multiple color 
channels, among cells with specific markers. 
Appendix B 
CellProfiler pipeline used for identification of Fos labeled nuclei in spinal cord 
Saved Pipeline, in file c-fos at 4XPIPE.txt, Saved on 02-Mar-2009 















Module #1: LoadImages revision - 2 
     How do you want to load these files?    Order 
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     Type the text that one type of image has in common (for TEXT options), or their 
position in each group (for ORDER option):    1 
     What do you want to call these images within CellProfiler?    Original 
     Type the text that one type of image has in common (for TEXT options), or their 
position in each group (for ORDER option). Type "Do not use" to ignore:    2 
     What do you want to call these images within CellProfiler? (Type "Do not use" to 
ignore)    LaminaeOriginal 
     Type the text that one type of image has in common (for TEXT options), or their 
position in each group (for ORDER option):    Do not use 
     What do you want to call these images within CellProfiler?    Do not use 
     Type the text that one type of image has in common (for TEXT options), or their 
position in each group (for ORDER option):    Do not use 
     What do you want to call these images within CellProfiler?    Do not use 
     If using ORDER, how many images are there in each group (i.e. each field of view)?    
2 
     What type of files are you loading?    individual images 
     Analyze all subfolders within the selected folder?    Yes 
     Enter the path name to the folder where the images to be loaded are located. Type 
period (.) for default image folder.    . 
     Note - If the movies contain more than just one image type (e.g., brightfield, 
fluorescent, field-of-view), add the GroupMovieFrames module.    n/a 
 
Module #2: IdentifyPrimAutomatic revision - 12 
 163 
     What did you call the images you want to process?    LaminaeOriginal 
     What do you want to call the objects identified by this module?    Laminae 
     Typical diameter of objects, in pixel units (Min,Max):    0,1000 
     Discard objects outside the diameter range?    No 
     Try to merge too small objects with nearby larger objects?    No 
     Discard objects touching the border of the image?    Yes 
     Select an automatic thresholding method or enter an absolute threshold in the range 
[0,1].  To choose a binary image, select "Other" and type its name.  Choosing ''All'' will 
use the Otsu Global method to calculate a single threshold for the entire image group. 
The other methods calculate a threshold for each image individually. "Set interactively" 
will allow you to manually adjust the threshold during the first cycle to determine what 
will work well.    .98 
     Threshold correction factor    1 
     Lower and upper bounds on threshold, in the range [0,1]    0,1 
     For MoG thresholding, what is the approximate fraction of image covered by objects?    
0.01 
     Method to distinguish clumped objects (see help for details):    None 
      Method to draw dividing lines between clumped objects (see help for details):    None 
     Size of smoothing filter, in pixel units (if you are distinguishing between clumped 
objects). Enter 0 for low resolution images with small objects (~< 5 pixel diameter) to 
prevent any image smoothing.    Automatic 
     Suppress local maxima within this distance, (a positive integer, in pixel units) (if you 
are distinguishing between clumped objects)    Automatic 
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     Speed up by using lower-resolution image to find local maxima?  (if you are 
distinguishing between clumped objects)    Yes 
     Enter the following information, separated by commas, if you would like to use the 
Laplacian of Gaussian method for identifying objects instead of using the above settings: 
Size of neighborhood(height,width),Sigma,Minimum Area,Size for Wiener 
Filter(height,width),Threshold    Do not use 
     What do you want to call the outlines of the identified objects (optional)?    
LaminaeOutlines 
     Do you want to fill holes in identified objects?    Yes 
     Do you want to run in test mode where each method for distinguishing clumped 
objects is compared?    No 
Module #3: InvertIntensity revision - 1 
     What did you call the image to be inverted (made negative)?    Original 
     What do you want to call the inverted image?    inverted 
Module #4: ApplyThreshold revision - 4 
     What did you call the image to be thresholded?    inverted 
     What do you want to call the thresholded image?    thresholded 
     Pixels below this value (Range = 0-1) will be set to zero (0 will not threshold any 
pixels)    0.4 
     If your answer was not 0, do you want to shift the remaining pixels'' intensities down 
by that intensity or retain their original values?    Retain 
     Pixels above this value (Range = 0-1) will be set to zero (1 will not threshold any 
pixels)    1 
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     If your answer was not 1, you can expand the thresholding around those excluded 
bright pixels by entering the number of pixels to expand here:    0 
     Binary option: Enter the threshold to use to make the incoming image binary (black 
and white) where pixels equal to or below this value will be zero and above this value 
will be 1. If instead you want to use the settings above to preserve grayscale information, 
enter 0 here.    0 
Module #5: IdentifyPrimAutomatic revision - 12 
     What did you call the images you want to process?    thresholded 
     What do you want to call the objects identified by this module?    FosNuclei 
     Typical diameter of objects, in pixel units (Min,Max):    5,13 
     Discard objects outside the diameter range?    Yes 
     Try to merge too small objects with nearby larger objects?    No 
     Discard objects touching the border of the image?    Yes 
     Select an automatic thresholding method or enter an absolute threshold in the range 
[0,1].  To choose a binary image, select "Other" and type its name.  Choosing ''All'' will 
use the Otsu Global method to calculate a single threshold for the entire image group. 
The other methods calculate a threshold for each image individually. "Set interactively" 
will allow you to manually adjust the threshold during the first cycle to determine what 
will work well.    Otsu Global 
     Threshold correction factor    1 
     Lower and upper bounds on threshold, in the range [0,1]    0,1 
     For MoG thresholding, what is the approximate fraction of image covered by objects?    
0.01 
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     Method to distinguish clumped objects (see help for details):    Shape 
      Method to draw dividing lines between clumped objects (see help for details):    
Intensity 
     Size of smoothing filter, in pixel units (if you are distinguishing between clumped 
objects). Enter 0 for low resolution images with small objects (~< 5 pixel diameter) to 
prevent any image smoothing.    Automatic 
     Suppress local maxima within this distance, (a positive integer, in pixel units) (if you 
are distinguishing between clumped objects)    Automatic 
     Speed up by using lower-resolution image to find local maxima?  (if you are 
distinguishing between clumped objects)    No 
     Enter the following information, separated by commas, if you would like to use the 
Laplacian of Gaussian method for identifying objects instead of using the above settings: 
Size of neighborhood(height,width),Sigma,Minimum Area,Size for Wiener 
Filter(height,width),Threshold    Do not use 
     What do you want to call the outlines of the identified objects (optional)?    
FosNucleiOutlines 
     Do you want to fill holes in identified objects?    Yes 
     Do you want to run in test mode where each method for distinguishing clumped 
objects is compared?    No 
Module #6: MeasureObjectAreaShape revision - 3 
     What did you call the objects that you want to measure?    FosNuclei 
        Do not use 
        Do not use 
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        Do not use 
        Do not use 
        Do not use 
        Do not use 
     Would you like to calculate the Zernike features for each object (with lots of objects, 
this can be very slow)?    No 
Module #7: MeasureObjectIntensity revision - 2 
     What did you call the greyscale images you want to measure?    Original 
     What did you call the objects that you want to measure?    FosNuclei 
        Do not use 
        Do not use 
        Do not use 
        Do not use 
        Do not use 
Module #8: Relate revision - 2 
     What objects are the children objects (subobjects)?    FosNuclei 
     What are the parent objects?    Laminae 
     What other object do you want to find distances to? (Must be one object per parent 
object, e.g. Nuclei)    None 
Module #9: OverlayOutlines revision - 2 
     On which image would you like to display the outlines?    inverted 
     What did you call the outlines that you would like to display?    LaminaeOutlines 
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     Would you like to set the intensity (brightness) of the outlines to be the same as the 
brightest point in the image, or the maximum possible value for this image format?    
Max possible 
     What do you want to call the image with the outlines displayed?    LaminaeImage 
     For color images, what do you want the color of the outlines to be?    White 
Module #10: ConvertToImage revision - 1 
     What did you call the objects you want to convert to an image?    FosNuclei 
     What do you want to call the resulting image?    FosNucleiImage 
     What colors should the resulting image use?    Binary (black & white) 
     For COLOR, what do you want the colormap to be?    Default 
Module #11: ImageMath revision - 1 
     What do you want to call the resulting image?    AnalyzedImage 
     Choose first image:    LaminaeImage 
     Choose second image, or "Other..." and enter a constant. Note: if the operation chosen 
below is ''Complement'', this second image will not be used    FosNucleiImage 
     What operation would you like performed?    Add 
     Enter a factor to multiply the first image by (before other operations):    1 
     Enter a factor to multiply the second image by (before other operations):    1 
     Do you want negative values in the image to be set to zero?    Yes 
     Do you want values greater than one in the image to be set to one?    Yes 
Module #12: SaveImages revision - 14 
     What did you call the images you want to save? If you would like to save an entire 
figure, enter the module number here    AnalyzedImage 
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     Which images'' original filenames do you want use as a prefix for these new images'' 
filenames? Your choice MUST be images loaded directly with a Load module. 
Alternately, type N to use sequential numbers for the file names, or type 
=DesiredFilename to use the single file name you specify (replace DesiredFilename with 
the name you actually want) for all files (this is *required* when saving an avi movie).    
Original 
     Enter text to append to the image name, type N to use sequential numbers, or leave 
"Do not use" to not append anything.    _analyzed 
     In what file format do you want to save images (figures must be saved as fig, which is 
only openable in Matlab)?    tif 
     Enter the pathname to the directory where you want to save the images.  Type period 
(.) for default output directory or ampersand (&) for the directory of the original image.    
. 
     Enter the bit depth at which to save the images (Note: some image formats do not 
support saving at a bit depth of 12 or 16; see Matlab''s imwrite function for more details.)    
8 
     Do you want to always check whether you will be overwriting a file when saving 
images?    No 
     At what point in the pipeline do you want to save the image? When saving in avi 
(movie) format, choose Every cycle.    Every cycle 
     If you are saving in avi (movie) format, do you want to save the movie only after the 
last cycle is processed (enter ''L''), or after every Nth cycle (1,2,3...)? Saving movies is 
time-consuming. See the help for this module for more details.    L 
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     Do you want to rescale the images to use a full 8 bit (256 graylevel) dynamic range (Y 
or N)? Use the RescaleIntensity module for other rescaling options.    Yes 
     For grayscale images, specify the colormap to use (see help). This is critical for movie 
(avi) files. Choosing anything other than gray may degrade image quality or result in 
image stretching.    gray 
     Enter any optional parameters here (''Quality'',1 or ''Quality'',100 etc.) or leave "Do not 
use" for no optional parameters.    Do not use 
     Update file names within CellProfiler? See help for details.    No 
     Do you want to create subdirectories in the output directory to match the input image 
directory structure? (Note: This option cannot be used with the "N" or 
"=DesiredFilename" option above)    Yes 
     Warning! It is possible to overwrite existing files using this module!    n/a 
Module #13: ExportToExcel revision - 1 
     Which objects do you want to export?    Image 
        Laminae 
        FosNuclei 
        Do not use 
        Do not use 
        Do not use 
        Do not use 
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Scope and Method of Study:  The purpose of this study was to examine the distribution of 
the enzyme glutaminase in rat dorsal root ganglion and determine its potential as a 
target for analgesic development.  The study used a combination of behavioral 
analysis and quantitative microscopy to investigate the distribution of glutaminase 
in the rat dorsal root ganglion, expression of glutaminase during inflammation, 
expression of glutaminase under conditions of nerve growth factor depletion, and 
effect of glutaminase inhibition on inflammation induced Fos expression in spinal 
cord. 
 
Findings and Conclusions:  Glutaminase was found to be distributed ubiquitously in rat 
dorsal root ganglion neurons.  Past discrepancies on its distribution were 
attributed to tissue fixation methods, and optimization of tissue fixation proved 
useful in properly identifying distributions of other proteins in the dorsal root 
ganglion.  Glutaminase expression in dorsal root ganglion neurons was increased 
after four days of hind paw inflammation and remained elevated after eight days 
in small diameter neurons.  Autoimmunization with nerve growth factor was 
effective at depleting nerve growth factor levels and causing hypoalgesia as had 
been reported previously.  Deprivation of nerve growth factor did not alter basal 
expression of glutaminase in dorsal root ganglion neurons, but it did decrease 
expression the voltage-gated sodium channel Nav1.8 in small isolectin B4 
negative neurons.  Lastly, peripheral inhibition of glutaminase during carrageenan 
induced inflammation decreased spinal cord Fos expression, which is typically an 
indicator of nociceptive activity at the spinal level.  Clarification of glutaminase 
distribution, understanding its basal regulation and in response to inflammation, 
and demonstrating the effectiveness of its inhibition at decreasing activity in pain 
pathways gave support for nomination of glutaminase as a novel therapeutic 
target for inflammatory pain. 
 
